Michigan Technological University

Digital Commons @ Michigan Tech
Dissertations, Master's Theses and Master's Reports
2019

THE OREXIN SYSTEM IN DOCA-SALT HYPERTENSION:
REGULATION OF VASOPRESSIN
Jeremy Bigalke
Michigan Technological University, jabigalk@mtu.edu

Copyright 2019 Jeremy Bigalke
Recommended Citation
Bigalke, Jeremy, "THE OREXIN SYSTEM IN DOCA-SALT HYPERTENSION: REGULATION OF VASOPRESSIN",
Open Access Master's Thesis, Michigan Technological University, 2019.
https://doi.org/10.37099/mtu.dc.etdr/780

Follow this and additional works at: https://digitalcommons.mtu.edu/etdr
Part of the Cellular and Molecular Physiology Commons, and the Systems and Integrative Physiology
Commons

THE OREXIN SYSTEM IN DOCA-SALT HYPERTENSION: REGULATION OF
VASOPRESSIN

By
Jeremy A. Bigalke

A THESIS
Submitted in partial fulfillment of the requirements for the degree of
MASTER OF SCIENCE
In Kinesiology

MICHIGAN TECHNOLOGICAL UNIVERSITY
2019

© 2019 Jeremy A. Bigalke

This thesis has been approved in partial fulfillment of the requirements for the Degree of
MASTER OF SCIENCE in Kinesiology.

Department of Kinesiology and Integrative Physiology

Thesis Advisor:

Dr. Zhiying Shan

Committee Member:

Dr. Qing-hui Chen

Committee Member:

Dr. Jason Carter

Committee Member:

Dr. Feng Zhao

Department Chair:

Dr. Megan Frost

Table of Contents
List of figures ....................................................................................................... v
Acknowledgements ............................................................................................ vii
List of abbreviations............................................................................................. ix
Abstract ............................................................................................................... xi
1

2

Introduction.................................................................................................. 1
1.1

Overview ............................................................................................ 1

1.2

Blood Pressure Regulation ................................................................ 1
1.2.1 Short Term Blood Pressure Regulation: Autonomic Influences
2
1.2.2 Long Term Blood Pressure Regulation: Hormonal Influences 4
1.2.2.1 Aldosterone and Arginine Vasopressin in Blood
Pressure Regulation .............................................................. 6

1.3

Hypertension ...................................................................................... 9

1.4

Salt Sensitive Hypertension (SSH) .................................................. 11
1.4.1 Dahl Salt-Sensitive Rat Model ............................................. 13
1.4.2 DOCA-salt Rat Model........................................................... 14

1.5

Neuro-hormonal Mechanisms in Dahl and DOCA-salt Models ........ 15
1.5.1 AVP in Dahl and DOCA Models of Hypertension ................. 17

1.6

Pharmaceutical Interventions ........................................................... 18

1.7

Orexin System ................................................................................. 20
1.7.1 Orexin Effect on Blood Pressure .......................................... 21
1.7.2 Orexin in Salt Sensitive Hypertension .................................. 24

1.8

Hypothesis ....................................................................................... 25

Methods..................................................................................................... 28
2.1

Animals ............................................................................................ 28

2.2

Paraventricular Nucleus Microinjections .......................................... 28

2.3

DOCA Pellet Implantation ................................................................ 29

2.4

Blood Pressure Measurement.......................................................... 30

2.5

Metabolic Measurements ................................................................. 31

2.6

Real Time PCR and Immunostaining ............................................... 32

2.7

Plasma AVP and CSF Orexin A ELISA Testing ............................... 33
iii

3

2.8

Intracerebroventricular Injections ..................................................... 33

2.9

Data Collection and Analysis ........................................................... 34

Results ...................................................................................................... 36
3.1 DOCA-salt Treatment Increases PVN AVP and OX1R mRNA and
Protein Expression .................................................................................... 36
3.2

DOCA-salt Treatment Increases Plasma AVP Concentration .......... 39

3.3

DOCA-salt Treatment Effect on Metabolism .................................... 40

3.4 Central Orexin-A Administration Increases Plasma AVP Concentration
in SD rats .................................................................................................. 42
3.5 Lateral Hypothalamic OXA Neuron Expression Remains Elevated
Following Chronic OX1R Knockdown........................................................ 44
3.6

Chronic PVN OX1R Knockdown Decreases OX1R Expression....... 46

3.7

Chronic PVN OX1R Knockdown Reduces Central AVP Production 47

3.8 Chronic PVN OX1R Knockdown Decreases Plasma AVP
Concentration ............................................................................................ 49
3.9

Chronic PVN OX1R Knockdown Effects on Metabolism .................. 52

3.10 Cardiac Hypertrophy is Partially Attenuated by PVN OX1R Knockdown
......................................................................................................... 54
3.11 PVN OX1R Knockdown Attenuates Elevation of Blood Pressure in
DOCA-salt Rats ......................................................................................... 55
4

Discussion ................................................................................................. 58
4.1

Implications ...................................................................................... 62

4.2

Limitations ........................................................................................ 63

4.3

Conclusion ....................................................................................... 64

5

Reference List ........................................................................................... 66

A

Raw Data................................................................................................... 76

B

Statistical Analysis ..................................................................................... 84

iv

List of figures
Figure 1.1: Diagram representing function of the Renin-Angiotensin-Aldosterone
system (RAAS) in blood pressure regulation. ...................................................... 5
Figure 1.2: Representation of aldosterone action on cells of the distal collecting
tubule of the kidney. ............................................................................................ 7
Figure 1.3: The mechanism of AVP on its two receptors, V1 (Vasopressin 1
Receptor) and V2 (Vasopressin 2 Receptor) in vascular smooth muscle cells and
the collecting duct of the kidney. ......................................................................... 9
Figure 1.4: Although orexin production only occurs within neurons located in the
Lateral Hypothalamus, vast axonal projections to other brain areas allow orexin to
carry out functions in multiple physiological processes. .................................... 21
Figure 1.5: Representative model of the hypothesized mechanism underlying
orexin control of blood pressure in the DOCA-rat model.. ................................. 27
Figure 2.1: Representation of Tail-Cuff Plethysmography procedural acclimation
and subsequent BP measurements................................................................... 31
Figure 2.2: Representative diagram showing the number of rats from each
experiment during the project and what physiological analysis was performed on
each................................................................................................................... 35
Figure 3.1: PVN AVP mRNA expression following 3-weeks of DOCA-salt
treatment. .......................................................................................................... 37
Figure 3.2: Representative immunostaining images of AVP protein expression in
control (left) and DOCA-salt (right) rats. ............................................................ 38
Figure 3.3: PVN OX1R mRNA expression following 3-weeks of DOCA-salt
treatment. .......................................................................................................... 38
Figure 3.4: Representative immunostaining images showing expression of the
orexin-1 receptor (OX1R) in the PVN in both control (left) and DOCA-salt (right)
rats. ................................................................................................................... 39
Figure 3.5: Plasma AVP concentrations (pg/ml) in control (n=4) and DOCA-HS
(n=8) treatment groups ...................................................................................... 40
Figure 3.6: 24-hour metabolic data of control (n=4) and DOCA-salt (n=3) treated
rats following 3-weeks of treatment. .................................................................. 41
v

Figure 3.7: Difference in body weight from beginning and end of treatment.
DOCA-salt (n=7) treatment results in a significant attenuation of weight gain
compared to control rats (n=6) .......................................................................... 42
Figure 3.8: Plasma AVP concentrations (pg/ml) following ICV injection of saline
(0.9%) (n=3) or OXA (2nmol) (n=3).. ................................................................. 43
Figure 3.9: Representative immunostaining images showing expression of
orexin-A (OXA) within (A) the lateral hypothalamus (LH) as well as (B) the
Paraventricular Nucleus of the Hypothalamus................................................... 45
Figure 3.10: PVN OX1R mRNA levels of expression normalized to GAPDH
expression. ........................................................................................................ 46
Figure 3.11: Representative immunostaining images showing orexin-1 receptor
(OX1R) expression within the PVN of control, DOCA-salt, and DOCA-salt rats
injected with AAV2-OX1R-shRNA into the PVN ................................................ 47
Figure 3.12: PVN AVP mRNA levels of expression normalized to GAPDH
expression. ........................................................................................................ 48
Figure 3.13: Representative immunostaining images showing arginine
vasopressin (AVP) expression within the PVN of control (far left), DOCA-salt
(middle left), and DOCA-salt rats injected with AAV2-OX1R-shRNA into the PVN
(middle right ....................................................................................................... 49
Figure 3.14: (A) Cerebrospinal fluid OXA concentration in control (n=5), DOCAHS (n=3), and DOCA HS-OX1RshRNA rats (n=3) ............................................ 50
Figure 3.15: 24-hour metabolic analysis of food and water intake as well as urine
and fecal output in all rats at the end of their respective treatments. ................. 52
Figure 3.16: Graph of the difference in weight between the beginning and end of
treatment in all groups ....................................................................................... 53
Figure 3.17: Quantification of cardiac hypertrophy through measurement of heart
weight to body weight ratio (HW:BW) ................................................................ 54
Figure 3.18: Mean arterial pressure (MAP) measurements over the course of 18
days as measured by tail-cuff plethysmography comparing control (n=5), DOCAsalt (n=4), and DOCA+OX1RshRNA (n=4) rats................................................. 56
Figure 3.19: Heart rate recordings taken in the same rats that received BP
measurements over the course of 18 days........................................................ 57

vi

Acknowledgements
I would first like to thank my advisor, Dr. Zhiying Shan, for her continued
guidance and full support in everything that I do, both in and out of lab. Dr. Shan’s
lessons and teachings have helped me develop both as a researcher, as well as
an individual, and I cannot thank her enough for all she has done. She has made
research both exciting and interesting, and has only given me a greater outlook
as I move forward in graduate school and life. I could not have asked for a better
mentor.
I would also like to thank all my committee members, Dr. Qinghui Chen,
Dr. Jason Carter, as well as Dr. Feng Zhao, for their willingness to help me through
my Master’s degree and all the assistance they have provided in writing my thesis.
I owe an enormous amount of gratitude to Dr. Erica Wehrwein, without
whom I would not be in graduate school in the first place. She instilled in me a
desire to always strive to learn more, and to take life head on without any
hesitation. She has shown me how to remain optimistic and curious, and has
offered a model of who I hope to resemble in the future. She has helped shape
me into the individual I am today, and I will forever be grateful.
I would also like to thank my friends and fellow graduate students for all of
the support they have given me during my time as a Master’s student. Namely, I’d
like to thank Dr. Andrew Chapp for teaching me many of the procedures utilized
in this study.
I am also very grateful for the generosity of Dr. Matthew and Mrs. Laura
Songer, whose monetary award, the Songer Research Award for Human Health
Research, has provided the primary source of funding for this project.
Last, but certainly not least, I would like to thank my family, especially my
parents, who from a young age taught me the importance of working hard and
vii

following whatever aspirations I may have. Most importantly, they taught me to
not turn away in the face of adversity, but rather work to overcome it and in doing
so, achieve my goals. I love you both very much!

viii

List of abbreviations
ANGII Angiotensin II
ANS Autonomic Nervous System
AVP Arginine Vasopressin
CO Cardiac Output
CVD Cardiovascular Disease
CVLM Caudal Ventrolateral Medulla
CVO Circumventricular Organs
DOCA Deoxycorticosterone Acetate
GABA Gamma Aminobutyric Acid
HS High Salt
ICV Intracerebroventricular
IML Intermediolateral Cell Column
MAP Mean Arterial Pressure
NTS Nucleus Tractus Solitarius
PNS Parasympathetic Nervous System
PVN Paraventricular Nucleus
RAAS Renin Angiotensin Aldosterone System
RVLM Rostral Ventrolateral Medulla
ix

SD Sprague Dawley
SFO Subfornical Organ
SNS Sympathetic Nervous System
SON Supraoptic Nucleus
SSH Salt Sensitive Hypertension
TPR Total Peripheral Resistance

x

Abstract
Orexin is a neuropeptide with a large range of functions, with a recently
discovered role in blood pressure (BP) regulation. Although the role of brain orexin
system in hypertension has been investigated in several hypertensive animals, it
remains unclear whether activation of the orexin system contributes to the
development of Deoxycorticosterone-acetate (DOCA) hypertension, an animal
model of human salt sensitive hypertension. In this study, we investigated the
hypothesis that Orexin-1 receptor (OX1R) expression is increased in the
paraventricular nucleus (PVN), a critical brain area controlling cardiovascular
function, which subsequently increases vasopressin (AVP) expression and
peripheral secretion, resulting in hypertension development in this model. Seven
to eight-week-old male Sprague Dawley (SD) rats were split into three groups
including DOCA-salt, untreated controls, and OX1RshRNA-DOCA rats. Following
knockdown of OX1R in the PVN via viral infection in the OX1RshRNA-DOCA rats,
they, as well as the DOCA-salt group, were implanted with a 75mg DOCA pellet
and treated with 1%NaCl/0.2%KCl drinking water, while the control group
remained untreated. Blood pressure of each rat was measured using tail-cuff
plethysmography. Three weeks following DOCA-salt or sham treatment, all rats
were sacrificed, and brains were subjected to either real-time PCR or
immunostaining to assay mRNA level and protein expression of Orexin A, OX1R,
and AVP in the PVN. Their blood was collected for plasma AVP measurement,
and their hearts were weighed for measurement of their heart weight/body weight
(BW/HW) ratio. Our results showed that chronic knockdown of the PVN OX1R
effectively attenuated hypertension induced by DOCA-salt treatment (control:
107.91±5.99 vs. DOCA-salt: 142.43±7.73 vs. DOCA+OX1RshRNA: 115.69±8.23
mmHg; P<0.01) PCR data showed the mRNA levels of OX1R was increased by
23%, while vasopressin showed more than a 2-fold increase in the PVN of DOCAsalt rats compared to controls. Immunostaining data showed a dramatic increase
in OX1R as well as vasopressin expression within the PVN following DOCA-salt
xi

treatment, and both increases were attenuated following PVN OX1R knockdown.
Plasma AVP levels also showed a significant increase following DOCA-salt
treatment (control: 9.04±2.57 vs. DOCA-salt: 37.94±8.66 pg/ml; P<0.05), and
PVN OX1R significantly attenuated this (DOCA-OX1RshRNA: 0.644±0.281,
P<0.05). The heart weight to body weight ratio was also measured to be larger in
the DOCA-salt group when compared to the control group (Control: 0.31±0.011%,
vs DOCA-salt: 0.40±0.017%, P<0.005), while the OX1RshRNA injection
appeared to mitigate this increase (OX1RshRNA: 0.35±0.019%, vs DOCA-salt:
DOCA-salt: 0.40±0.017%). The combination of this data shows a potential role for
orexin in the pathology of salt-sensitive hypertension development.

xii

1 Introduction
1.1 Overview
Hypertension is a major pathological condition that affects millions of
individuals, and approximately one-third of adults in the United States alone
(Centers for Disease and Prevention 2011). Along with the various
pathophysiological traits that accompany the onset of hypertension, individuals
who are affected are also at an increased risk for devastating cardiovascular
diseases, such as cardiac ischemia, hearty failure, and stroke (Klungel, Kaplan et
al. 2000, Drazner 2011, Turin, Okamura et al. 2016), both of which raise the
likelihood of death due to cardiovascular complications. A plethora of studies have
found that the majority of individuals who are diagnosed with primary hypertension
are often known as salt-sensitive, meaning that sodium handling and pressor
responses following a salt challenge are faulty, leading to an increase and
maintenance of an abnormally high blood pressure (Weinberger 1996, Whelton,
Appel et al. 2012, O'Donnell, Mente et al. 2015). Although it is estimated that
slightly more than half of individuals diagnosed with high blood pressure are
considered salt-sensitive (Weinberger, Miller et al. 1986), very little is known about
the molecular mechanism underlying the abnormal response to sodium intake.
Because of this, it is important to produce new knowledge and deeper insight into
the mechanism underlying Salt-Sensitive Hypertension (SSH) to decrease its
prevalence in the general population, thus decreasing cardiovascular disorders,
as well as the associated mortality rate.

1.2 Blood Pressure Regulation
Current American Heart Association guidelines for hypertension state that a
blood pressure of 120/80 mmHg is classified as normotensive (Whelton, Carey et
al. 2018). To maintain a relatively constant blood pressure, the body has
employed various means of regulating this stable environment. Mean arterial
1

pressure (MAP) is defined as the average blood pressure experienced by an
individual over one cardiac cycle. MAP is the product of both cardiac output (CO)
and total peripheral resistance (TPR). This offers two variables that must be in
working condition to efficiently regulate blood pressure. However, there are
numerous ways in which the body can modify CO as well as TPR, specifically
through autonomic and neural-hormonal signaling, which act as short-term and
long-term means of blood pressure management.
1.2.1 Short Term Blood Pressure Regulation: Autonomic Influences
As the heart pumps blood throughout the body, the cardiovascular system
is notified on a beat-by-beat basis of any abnormalities in blood flow, primarily by
the action of the two branches of the autonomic nervous system (ANS): the
parasympathetic nervous system (PNS) and the sympathetic nervous system
(SNS). The PNS and SNS have antagonistic actions in relation to one another,
although both are intrinsically active (Swenne 2013). The PNS serves as the
mediator of action during resting phases, while the SNS elicits excitation and
increased activity. In blood pressure regulation, the SNS innervates the sinoatrial
(SA) node, also known as the pacemaker, in the right atrium of the heart, as well
as the myocardium. Because of this, when activated, the SNS can increase heart
rate, as well as cardiac contractility, thus effecting stroke volume. The PNS
opposes this action, and innervates the SA node through the vagus nerve, which,
when activated, causes a decrease in heart rate. Along with this, innervation of
blood vessels by the SNS results in vasoconstriction, which can also increase
TPR.
The PNS and SNS are activated and regulated through the actions of
baroreceptors. Baroreceptors function as mechanoreceptors, and are primarily
located in both the carotid sinus and the aortic arch. These mechanoreceptors
respond to any changes in the pressure against blood vessel walls that may
indicate a dysfunction in the regular flow of blood through the cardiovasculature
2

(Charkoudian and Rabbitts 2009). When a change is observed by the
mechanoreceptors, they activate the body’s intrinsic baroreflex mechanism
(Charkoudian and Rabbitts 2009). When the mean arterial pressure is increased,
the increase in blood volume stretches vessel walls and is sensed in both the
aortic arch, as well as the carotid sinus, which are innervated by the vagus nerve
and the glossopharyngeal nerve (Benarroch 2008), respectively. This immediately
increases afferent signal firing frequency from the baroreceptors to the
cardiovascular control center located within the medulla oblongata of the
brainstem, specifically the nucleus tractus solitarius (NTS) (Guyenet 2006,
Dampney 2016). The NTS acts as a key cardiovascular integration center, and
functions to activate inhibitory interneurons through glutamate release within the
caudal ventrolateral medulla (CVLM). The CVLM elicits an inhibitory effect
through release of the neurotransmitter Gamma-Aminobutyric Acid (GABA) on the
rostral ventrolateral medulla (RVLM) (Kumagai, Oshima et al. 2012), the location
of many pre-sympathetic neurons and a key center for sympathetic output
(Pilowsky and Goodchild 2002). This pathway causes a cessation of sympathetic
efferent output, and an increase in PNS activity. This effectively decreases both
heart rate and stroke volume, decreasing cardiac output, and causes vasodilation
of the vasculature, reducing the total peripheral resistance, allowing the blood
pressure to fall back to its normotensive state. If an individual becomes
hypotensive, the opposite occurs, and sympathetic nerve activity is increased
through a reduced inhibition of the RVLM, resulting in subsequent glutamatergic
activation of sympathetic preganglionic neurons within the intermediolateral cell
column (IML) (Guyenet 2006, Kumagai, Oshima et al. 2012), resulting in an
increase in cardiac output as well as vasoconstriction, effectively raising blood
pressure. Although this mechanism allows an efficient means of monitoring blood
pressure on a short-term basis, it is not meant to be a long-term solution to blood
pressure dysregulation.
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1.2.2 Long Term Blood Pressure Regulation: Neural-Hormonal Influences
To compensate for long term adaptations to blood pressure changes, the
human body produces multiple hormones in response to changes in blood
pressure, which can carry out their function over a much longer period of time.
The Renin-Angiotensin-Aldosterone-System (RAAS) is the predominant controller
of this hormonal response, and acts as the primary controller of long-term blood
pressure regulation through modulation of both natriuresis and diuresis within the
kidney tubules. When blood pressure lowers to a level that is classified as
hypotensive, or the osmolality of the blood reaches a lower level than the norm,
the kidneys will release renin, an important catalytic enzyme that facilitates the
transformation of circulating Angiotensinogen to Angiotensin I (ANGI).
Angiotensin Converting Enzyme (ACE) then turns Angiotensin I into Angiotensin
II (ANGII). ANGII is arguably one of the most important, and potent hormones
involved in blood pressure regulation. ANGII carries out its primary activity through
two receptors, AT1 and AT2 receptors. Although the actions of ligand binding to
AT2 receptors are not as well understood, binding of ANGII to its AT1 receptor
facilitates an increase in sympathetic tone as well as vasoconstriction. ANGII also
heavily influences the synthesis and subsequent release of two major hormones,
aldosterone and vasopressin (AVP) (Fig. 1.1).
Further research has observed that ANGII may also have influences on brain
function and subsequent synaptic activity through interaction with the central
nervous system. All RAAS components have been found within the brain
(McKinley, Allen et al. 2001, McKinley, Albiston et al. 2003, Pan 2004), indicating
an intrinsic central mechanism for RAAS functioning. It is also worth mentioning
that the bulk concentration of AT1 receptors, are found in major cardiovascular
areas such as the PVN and Supraoptic Nucleus (SON) (Pan 2004). Studies have
shown that an ANGII brain injection, whether it be intracerebroventricular (ICV) or
through direct microinjection into the PVN, elicits an increase in blood pressure,
4

and antagonism of the AT1 receptor within the brain causes a dampening of the
blood pressure increase (Jensen, Harding et al. 1992, Bahner, Geiger et al. 1995).
Interestingly, it has also been observed that subcutaneous and peripheral
injections of ANGII have shown an increase in AT1 receptors within the PVN,
despite the presence of the blood brain barrier, which ANGII cannot readily cross
(Wei, Yu et al. 2009). Although it cannot directly elicit a response on major brain
areas, ANGII acts on AT1 receptors within Circumventricular Organs (CVO) such
as the vascular organ of lamina terminalis (OVLT), subfornical organ (SFO), the
median eminence, and the area postrema, all of which lack a blood brain barrier
(Sunn, McKinley et al. 2003, Pan 2004). These brain regions have high
concentrations of AT1 receptors (Pan 2004), as well as multiple projections to
other brain areas, namely, projections from the SFO to the PVN (Kawano and
Masuko 2010). This offers an explanation as to why peripheral actions of ANGII
in response to lowered blood pressure, or changes in blood osmolality, can elicit
a centrally mediated response in cardiovascular control centers, such as the PVN.
SNA +

Renin
Angiotensinogen

ACE
ANGI

Adrenal Gland

Aldosterone
Na+ and H2O
Reabsorption,
K+ Secretion,
↑BP

ANGII

+

Posterior
Pituitary

Decrease BP

-

AVP

Vasoconstriction

Figure 1.1: Diagram representing function of the Renin-Angiotensin-Aldosterone
system (RAAS) in blood pressure regulation. Angiotensin I (ANGI), AngiotensinConverting Enzyme (ACE), Angiotensin II (ANGII), Sympathetic Nerve Activity (SNA),
Arginine Vasopressin (AVP), Blood Pressure (BP).
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1.2.2.1 Aldosterone and Arginine Vasopressin in Blood Pressure Regulation
Aldosterone was first discovered in 1953, and since that time, it has been
recognized as a major regulator of fluid and electrolyte balance within the kidney
natriuresis/diuresis system. Aldosterone is a mineralocorticoid that is produced by
the adrenal cortex upon stimulation from various factors, such as circulating
ANGII, increased serum potassium levels, among others (Briet and Schiffrin
2010). Upon activation and subsequent release from the adrenal glomerulosa,
aldosterone acts on both glucocorticoid as well as mineralocorticoid receptors
within the cytoplasm of target tissues, with a higher affinity for the latter (Muto
1995). After binding to its receptor, the hormone-receptor complex will relocate to
the nucleus of the cell, and mediate regulation of gene transcription (Muto 1995).
These genes will then lead to the production of proteins that work to preserve fluid
homeostasis within the body, specifically through regulation of electrolyte (sodium
and potassium) levels within the bloodstream (Muto 1995, Summa, Mordasini et
al. 2001). One of the downstream transcription regulation pathways occurs in cells
of the distal convoluted tubule of the kidney, where binding of aldosterone causes
downstream activation of epithelial sodium channels (ENaC) on the apical
membrane of the epithelial cells, as well as Na+/K+ ATPase on the basolateral
side, resulting in a net sodium, and subsequent water reabsorption, as well as
potassium excretion into the urine (Summa, Mordasini et al. 2001, Briet and
Schiffrin 2010). This process effectively increases blood osmolality as well as
volume, making it essential to proper functioning of the complete RAAS system
(Fig. 1.2).
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Collecting
Tubule Cell

Urine

Blood

Aldosterone

MR
+
Na+

ENaC

+
K+

ATPase

Na+

K+

Figure 1.2: Representation of aldosterone action on cells of the distal collecting
tubule of the kidney. Mineralocorticoid receptor (MR), Sodium/Potassium ATPase
(ATPase), endothelial sodium channel (ENaC), sodium (Na+), potassium (K+).
Another key hormone in cardiovascular and fluid homeostasis is Arginine
Vasopressin (AVP). AVP is produced in both magnocellular as well as
parvocellular neurons located in both the (PVN) of the Hypothalamus as well as
the SON (Treschan and Peters 2006). It is primarily activated by an increase in
plasma osmolality, decreased blood volume, as well as decreased arterial
pressure (Treschan and Peters 2006). Through its action on its three receptor
types (V1, V2, V3), AVP can elicit multiple physiological responses. Worth noting,
AVP specifically causes vasoconstriction through its interaction with V1 receptors
on smooth muscle cells, and causes water reabsorption through relocation of
aquaporins on the collecting ducts of the kidney through its interaction with V2
receptors (Thibonnier, Berti-Mattera et al. 1998, Bankir, Fernandes et al. 2005,
Treschan and Peters 2006). The V1 and V2 receptors are two different types of
G-protein Coupled Receptors (GPCRs), with differing downstream signaling
cascades. The V1 cascade involves interaction with phospholipase C (PLC)
following conformational change of the GPCR upon substrate binding. PLC then
7

acts to facilitate the cleavage of inositol 4,5 – bisphosphate (PIP2) into inositol
1,4,5 – trisphosphate (IP3) and diacyglycerol (DAG) (Thibonnier, Berti-Mattera et
al. 1998, Treschan and Peters 2006). IP3 is a secondary messenger that, upon
diffusion through the cell, binds to a calcium channel located within the
endoplasmic reticulum (ER). Upon binding, calcium is released into the cytosol,
which mediates activation of various further calcium regulated intracellular
signals. These secondary messengers then act on other enzymes, resulting in
vasoconstriction (Thibonnier, Berti-Mattera et al. 1998, Treschan and Peters
2006). V2 receptors act through a slightly different mechanism, stimulating the
adenylate cyclase pathway, resulting in activation of various protein kinases via
activation by the secondary messenger cAMP, eventually resulting in aquaporin2 transcription and protein formation followed by relocation into the membrane of
the collecting ducts of the kidneys, allowing water reabsorption (Treschan and
Peters 2006). This process effectively decreases blood osmolality, while
increasing plasma volume (Fig.1.3).
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AVP
V1

V2

α β ϒ

α β ϒ

α

GTP

α AC
ATP

PLC

cAMP

DAG

PIP2

AQ-2

IP3

ER

Water
Reabsorption

Ca2+

Vasoconstriction

PKA

↑BP

Figure 1.3: The mechanism of AVP on its two receptors, V1 (Vasopressin 1
Receptor) and V2 (Vasopressin 2 Receptor) in vascular smooth muscle cells and
the collecting duct of the kidney. Arginine Vasopressin (AVP), Guanosine
triphosphate (GTP), phospholipase-C (PLC), inositol 4,5 – bisphosphate (PIP2),
diacyglycerol (DAG), inositol 1,4,5 – trisphosphate (IP3), endoplasmic reticulum
(ER), adenylate cyclase (AC), cyclic-AMP (cAMP), phosphokinase A (PKA),
aquaporin-2 (AQ-2), blood pressure (BP).
Although the implementation of these two blood pressure regulatory systems
is essential in maintaining proper blood volume, osmolality, and therefore
consistent pressure, any over-activation of either sympathetic activity or the RAS
can result in detrimental cardiovascular complications, of which, the mechanism
underlying the pathology is still poorly understood.

1.3 Hypertension
Hypertension is defined as an abnormally high blood pressure. When this
abnormality becomes a chronic condition, the individual is exposed to a higher
risk of further cardiovascular dysfunction, and serious disease that can result in
9

premature death. Not only this, hypertension also incurs a large healthcare
financial burden of approximately $131 billion per year (Kirkland, Heincelman et
al. 2018). The AHA’s recent guidelines go further in outlining three different levels
of hypertension: Elevated (120-129/80 mmHg), stage 1 (systolic anywhere
between130-139 mmHg or diastolic between 80-89 mmHg), and stage 2 (systolic
at least 140 mmHg or diastolic at least 90 mmHg) (Whelton, Carey et al. 2018).
These modifications to the former hypertension guidelines mean that an even
greater portion of the general population can be diagnosed with some variation or
differing level of hypertension, and thus require health intervention. Unfortunately,
there is no one known mechanism underlying hypertensive tendencies. In
addition, despite the numerous means of treatment currently available,
hypertension and cardiovascular disease (CVD) remain a major global issue.
Depending on the cause, hypertension has been split into two subtypes: primary
(essential) and secondary hypertension.
Primary hypertension is labelled such when the given hypertension has no
known cause. Approximately 90% of individuals who are currently diagnosed with
hypertension have primary hypertension (Carretero and Oparil 2000, Beevers, Lip
et al. 2001). There is currently no known cause for primary hypertension, given
the complex etiology of the disease and the differing symptoms and causative
factors among those afflicted by the condition. However, it is well established that
many lifestyle factors and behaviors may have a causative relation with
hypertension and CVD. Some of these factors include smoking, alcohol
consumption, high salt intake, sedentary lifestyle, and many more generally
correctable behaviors (Carretero and Oparil 2000, Bolivar 2013). In addition to the
multitude of environmental and behavioral factors associated with the
pathogenesis of primary hypertension, many researchers are also searching for a
common genetic abnormality among individuals with hypertension.
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The remaining approximately 10% of individuals with hypertension are
classified under secondary hypertension. Although the prevalence of secondary
hypertension is much smaller in proportion to the number of primary hypertensive
individuals, the effects of secondary hypertension are still a major health concern
worldwide. Secondary hypertension is named so because the hypertension is
secondary

to

some

other

abnormality,

such

as

kidney

disease,

hyperaldosteronism (Douma, Petidis et al. 2008, Puar, Mok et al. 2016),
obstructive sleep apnea (Pedrosa, Drager et al. 2011), obesity, and many others.
Although

secondary

hypertension

is

generally

curable,

the

underlying

mechanisms are not always well defined. However, it is important to investigate
the causes in order to prevent the development of resistant hypertension and
further cardiac complications, which becomes a risk for individuals who are left
undiagnosed.

1.4 Salt Sensitive Hypertension (SSH)
Over the years, the amount of salt used in meal preparation has drastically
increased. The Center for Disease Control has established guidelines outlining
how much salt should be ingested daily. Despite these guidelines, the average
amount of daily salt intake continues to increase, with average daily intake in the
United States alone reaching levels greater than 3200 mg/day (Bernstein and
Willett 2010), which is much more than the amount necessary for normal
physiological functioning. A correlation between excessive intake of dietary salt
and an increase in the risk of hypertension has been well established in literature
from animal and clinical studies (Whelton, Appel et al. 2012, O'Donnell, Mente et
al. 2015). This susceptibility of certain individuals to an abnormal increase in blood
pressure following salt intake has been termed “Salt Sensitive Hypertension”
(SSH). SSH is possibly one of the most prevalent types of hypertension, and
occurs when an individual’s blood pressure is abnormally increased following salt
intake. It has been suggested that approximately 51% of hypertensive individuals
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can be classified as salt-sensitive, while approximately 26% of normotensive
individuals are also salt-sensitive (Weinberger, Miller et al. 1986, Choi, Park et al.
2015). Despite the prevalence of this disorder, the pathology and mechanism are
still poorly understood, despite advancements in hypertension research.
Numerous reports have focused primarily on the effects of kidney
dysfunction as a primary cause of SSH. A previously outlined mechanism of
kidney control of blood pressure regulation was developed by Guyton (Coleman,
Granger et al. 1971, Guyton 1991), in which it is hypothesized that an increase in
salt intake, and resultant fluid ingestion, causes an increase in fluid volume within
the body. This will eventually lead to pressure natriuresis within the kidneys,
leading to excretion of both salt and water to enable the blood pressure to return
back to equilibrium (Guyton 1991). This model has been a classic representation
of what many researchers consider the primary controller of blood pressure
regulation via the kidneys. Any sort of dysfunction in this system would likely lead
to chronic hypertension. In a classic experiment performed by Lewis Dahl, saltsensitive and salt-resistant rats were subjected to a bilateral nephrectomy
followed by kidney transplant from either the same, or opposite strain. They were
then given a normal salt diet. They found that in rats receiving a kidney from a
salt-sensitive strain, the blood pressure increase was approximately 30 mmHg
greater than those rats that received a kidney from the salt resistant strain (Dahl,
Heine et al. 1974). This finding points to a key role of local genetics within the
kidneys in blood pressure changes in response to salt loading. This finding was
repeated, and a greater increase in blood pressure in resistant rats receiving
kidneys from sensitive rats when compared to those who received kidneys from
other resistant rats was observed (Morgan, DiBona et al. 1990). However, in the
same study, when given a high salt diet (8%Nacl) as opposed to a normal salt diet
(0.4%NaCl), salt sensitive rats who received kidney transplants from resistant rats
as well as fellow salt sensitive rats alike responded with similar increases in blood
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pressure after the salt loading, indicating that the kidneys alone may not be the
only regulators of blood pressure.
Because of this discrepancy, others have argued the potential for the brain
and the central nervous system as the primary source of dysfunction in SSH.
Multiple studies have shown that sympathetic outflow is increased following salt
intake (Leenen, Ruzicka et al. 2002, Fujita and Fujita 2013). As previously
mentioned, there is also evidence for central action of the RAAS following high
salt intake, which is specifically mediated through peripheral interactions with
CVO, and subsequent synaptic transmission to areas such as the PVN, which are
important in regulation of cardiovascular function (Pan 2004, Wei, Yu et al. 2009,
Kawano and Masuko 2010).
Clearly, the etiology and pathogenesis is a rather complex system that
requires a large deal of attention. Because there is no one clear mechanism
underlying SSH as of right now, multiple animal models have been utilized to
mimic SSH in humans, in order to find the molecular connections to SSH. Due to
various reasons, the primary animal model used in current hypertension research
is the rat (Pinto, Paul et al. 1998). Two of the most commonly used strains of rats
used specifically for SSH research are the Dahl Salt-Sensitive (Dahl S) and
Deoxycorticosterone Acetate (DOCA)-Salt rats, both of which will be the primary
focus for the remainder of this study.
1.4.1 Dahl Salt-Sensitive Rat Model
The Dahl S rat model was developed by researcher Lewis K. Dahl, who has
come to be known as a significant influence on salt-sensitivity research. During
his research on the effects of salt ingestion, he noticed that some of the Sprague
Dawley rats acquired hypertension, while some remained unaffected by the salt
treatment. He began to selectively inbreed those whose blood pressures
increased following salt intake with one another, as well as those who did not
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respond to the salt treatment. Following a few years of breeding, Dahl found that
he had successfully bred two strains of rats with statistically different reactions in
blood pressure to a high salt intake, and labelled them sensitive and resistant to
a high salt intake (Dahl, Heine et al. 1962). This salt sensitive strain eventually
became known as the Dahl Salt Sensitive rat model, and has since been a major
model used in salt sensitive hypertension research. The Dahl S rat model is
generally used as a model for genetic primary hypertension, as this model can
acquire hypertension even with normal salt intake (Pinto, Paul et al. 1998). Salt
sensitivity is an additive factor in the adequacy of this model. It is an effective
model because there is potential for genetic predisposition to salt-sensitivity in the
90% of individuals who can be classified under primary hypertension.
1.4.2 DOCA-salt Rat Model
The DOCA-salt rat model was originally developed in the 1970s. In this
SSH model, the combination of both DOCA pellet implantation and administration
of a salt drink solution (~1% NaCl) results in impaired renal handling of sodium,
eventually leading to hypertension development (Basting and Lazartigues 2017).
Often, this model is paired with uninephrectomy, which exaggerates the onset of
hypertension (Basting and Lazartigues 2017). This rat model offers a model for
primary aldosteronism, a term coined by Jerome Conn to describe excessive
production of aldosterone from the adrenal glands (Conn 1955). The development
of hypertension in this model is dependent on the excessive amounts of DOCA, a
mineralocorticoid and precursor to aldosterone, which results in excessive sodium
and water reabsorption, as well as potassium excretion in the kidneys (Yemane,
Busauskas et al. 2010, Basting and Lazartigues 2017). Because increased
aldosterone levels have been gaining more interest as a primary cause for
hypertension (Kaplan 2004, Tomaschitz, Pilz et al. 2010), the DOCA model offers
an adequate model of this pathology. The onset of hypertension with this specific
model is often observed to occur in stages, with an initial spike in blood pressure
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within the first couple of days, followed by a more gradual increase and
maintenance of an elevated blood pressure in the weeks following administration
(Yemane, Busauskas et al. 2010). This model’s etiology varies greatly from the
Dahl S rat model, in that it acts as a hypertensive model caused by excessive
adrenal steroid release and subsequent endocrine dysfunction, as opposed to the
primary genetic model observed in the Dahl S rat.

1.5 Neuro-hormonal Mechanisms in Dahl and DOCA-salt Models
Both rat models offer insight into two differing types of salt sensitive
hypertension, but both have been observed to show patterns of neural as well as
central hormonal mechanisms in response to a high salt intake. In the Dahl S
model, dysfunctional nervous system activity as well as baroreflex dysfunction is
commonly observed. Studies done on aortic nerve activation, which is part of the
afferent response to baroreflex activation, and regulation of baroreflex response
in prehypertensive Dahl S rats fed a low salt diet compared to Dahl Resistant
(Dahl R) rats found that prehypertensive Dahl S rats showed a significantly lower
baroreceptor discharge following phenylephrine infusion when compared to
resistant rats (Gordon and Mark 1984). The same group also found impaired SNA
activation and subsequent vascular responsiveness increase, resulting in a higher
TPR in prehypertensive Dahl S rats when compared to Dahl R rats (Gordon and
Mark 1983).

This relationship indicates that Dahl S rats have a genetic

predisposition leading to impaired baroreflex sensitivity even before hypertension
is fully developed. Further evidence showed that, following artificial volume
expansion of veins through the use of dextran, a high salt diet increased the neural
inhibitory response and potentiated the dampening of SNA in Dahl R rats, while
in Dahl S rats fed a high salt diet, cardiopulmonary baroreflex inhibition of SNA
was decreased, leading to an increase in SNA outflow to the splanchnic nerve
(Victor, Morgan et al. 1986). The combination of these studies shows that Dahl S
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rats have a compromised baroreflex and subsequent SNA response to arterial
pressure changes, most likely due to genetic predispositions.
Baroreflex dysfunction and excessive SNA have also been observed in the
DOCA rat model. However, because DOCA hypertension is generally
characterized by a sharp increase in blood pressure in the first few days, followed
by a more gradual increase in the following weeks (Yemane, Busauskas et al.
2010), there is some discrepancy on the magnitude of SNA input on the
development of hypertension as opposed to the input of hormonal signaling as
the primary cause of hypertension. In a few studies performed by deChamplain
(de Champlain, Krakoff et al. 1968, Bouvier and de Champlain 1986) it was
discovered that DOCA rats, when given 1% NaCl for an extended period of time,
are found to have reduced norepinephrine binding and storage in the heart,
meaning that there is more NE in the bloodstream. This was one of the first pieces
of evidence showing that sympathetic over activity played a role in DOCA-salt
hypertension during the fully developed phase of hypertension. However, others
have found that there was no increase in SNA during the early phases of
hypertension development (Yemane, Busauskas et al. 2010). This is important in
distinguishing the role that SNA plays in certain portions of hypertension
development in the DOCA rat. Further research has shown, similar to Dahl S rats,
that the baroreflex following aortic nerve stimulation is dampened in DOCA rats
compared to their controls (Takeda, Nakamura et al. 1988, Schenk and McNeill
1992).
Along with increased SNA following a HS intake, central RAAS function has
been extensively observed and studied. The Hypothalamus is an important center
for RAAS function (McKinley, Allen et al. 2001, Pan 2004), and as previously
stated, cardiovascular relevant areas such as the PVN have been found to hold a
large concentration of AT1 receptors, as well as AVP producing neurons (Pan
2004). Because of this, the brain RAAS has become a major focus in the
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pathology of Dahl S hypertension. Development of hypertension following a high
salt diet in Dahl S rats has repeatedly shown evidence of mediation through the
RAAS within the brain (Teruya, Muratani et al. 1995, Kubo and Hagiwara 2006).
Further studies have shown that ICV of hypertonic saline elicited a greater
increase in the blood pressure of Dahl S rats when compared to Dahl R or
normotensive rats (Huang, Wang et al. 2001, Kubo and Hagiwara 2006). This
response is thought to be mediated by an increase in cerebrospinal fluid sodium
concentration, which is sensed by the CVOs and transmitted to cardiovascular
relevant areas of the brain such as the PVN, activating the RAAS (Yang, Jin et al.
1992, Huang, Van Vliet et al. 2004). Inhibition of AT1 receptors has also been
shown to decrease the hypertension normally observed in Dahl S rats (Yang, Jin
et al. 1992, Gabor and Leenen 2012). A similar role for central RAAS activation
has also been observed in the DOCA rat model. Following DOCA pellet
implantation and high salt diet treatment, central RAAS has been shown to be a
common regulator of the hypertension development seen in this rat model (Basso,
Ruiz et al. 1981, Itaya, Suzuki et al. 1986, Gutkind, Kurihara et al. 1988). Also,
similar to the Dahl S model, knockdown of ANGII function following ICV injection
of captopril, an ACE inhibitor, has been shown to alleviate the elevated blood
pressure found in DOCA-salt rats, with no effect on normotensive rats (Itaya,
Suzuki et al. 1986). The combination of these studies in both rat models shows
the importance of SNA outflow and more importantly, RAAS activity, in the
pathogenesis of both forms of SSH.
1.5.1 AVP in Dahl and DOCA Models of Hypertension
Because of the importance of the RAAS in the development and
maintenance of elevated blood pressure in both primary and secondary SSH, as
well as the downstream effects of elevated RAAS activity on SNA outflow, it is
important to produce new knowledge concerning the dysregulation of central
hormonal responses following a high salt intake. One of the most important
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hormones and regulatory factors of blood pressure is AVP. It has become well
known that an increase in salt intake causes activation of osmoreceptors found in
the circumventricular organs due to the increased blood osmolarity and mineral
imbalances. The CVOs then send excitatory projections to the PVN, resulting in
an increased AVP synthesis within magnocellular neurons of the PVN. This AVP
is then stored within vesicles at the axon terminals that project from the PVN to
the neurohypophysis of the pituitary gland. Upon further stimulation, the PVN
neurons will release AVP directly from these terminals into systemic circulation.
As previously stated, this increase in AVP within the bloodstream results in
activation of V1 and V2 receptors, resulting in both vasoconstriction as well as
water reabsorption in the kidneys. Also, the significance of AVP upregulation in
both Dahl S and DOCA rats following a high salt challenge has been well
documented and extensively reviewed (Berecek, Barron et al. 1982, Berecek,
Murray et al. 1982, Schenk and McNeill 1992, Huber, Fan et al. 2017). Along with
these studies, microinjection of AVP has been shown to elicit an increase in SNA
outflow, and antagonism of the V1 receptor within the PVN reduced the SNA
outflow and blood pressure in salt-loaded rats (Ribeiro, Panizza Hdo et al. 2015).
Given the increased presence of AVP following salt loading in both neurogenic
and secondary forms of SSH, the potent regulatory effects of AVP on long term
blood pressure, the presence of elevated plasma AVP in human hypertension
patients (Os, Kjeldsen et al. 1986), and the regulatory effect of AVP on SNA
outflow (Ribeiro, Panizza Hdo et al. 2015), it is logical to assume that AVP overactivation within the PVN and SON and subsequent elevations in systemic
circulation following release from the neurohypophysis is critical to the
development and maintenance of hypertension.

1.6 Pharmaceutical Interventions
Because of the importance of RAAS activation and subsequent AVP
release, many pharmaceuticals used to treat hypertension are aimed towards
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decreasing RAAS function. Two of the most commonly used pharmaceutical
interventions are ACE Inhibitors and Angiotensin II Receptor Blockers (Jarari, Rao
et al. 2015). One study reported that over a five year period, ACE Inhibitors and
ANGII Receptor Blockers represented approximately 13.3 and 28.3% of
prescribed anti-hypertensive medications, respectively (Xu, He et al. 2015). In
practice, these drugs are used to diminish RAAS activity. Although the use of
these pharmaceutical interventions generally has a positive impact on improper
blood pressure regulation, studies have shown that an increase in salt intake has
an opposing action to hypertensive medications (Weinberger, Cohen et al. 1988,
Calhoun, Jones et al. 2008). In addition, excessive salt intake is believed to have
a direct impact on the development of resistant hypertension (Calhoun, Jones et
al. 2008), which is characterized as persistent hypertension despite the use of 3
or more anti-hypertensive prescription drugs. The prevalence of resistant
hypertension has been a point of contention, although studies generally observe
a prevalence in approximately 10-30% of hypertensive individuals (Calhoun,
Jones et al. 2008, Sim, Bhandari et al. 2013). Although the prevalence among the
general population is under dispute, primarily due to discrepancy in measurement
technique and diagnosis, it is generally shown that approximately 5-15% of the
population exhibit signs of primary aldosteronism (Douma, Petidis et al. 2008), the
same pathology modelled in the DOCA rat. However, in those individuals with
resistant hypertension, approximately 20% can also be diagnosed with primary
aldosteronism (Calhoun, Nishizaka et al. 2002, Eide, Torjesen et al. 2004). In
order to combat the decreased efficacy of traditional anti-hypertensive
interventions in resistant individuals, testing and use of anti-aldosterone,
aldosterone synthase inhibitors, as well as mineralocorticoid receptor antagonists
has gained recent attention as a possible addition to classic antihypertension drug
regiments (Oparil and Schmieder 2015), although there is still uncertainty in the
efficacy of these drugs. Despite new knowledge concerning regulation of blood
pressure in these hypertensive individuals, an exact mechanism underlying the
development of salt sensitive hypertension as well as drug resistance has not yet
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been discovered, nor have the central pathways that regulate RAAS and
subsequent AVP release following salt intake.

1.7 Orexin System
Orexin is a small neuropeptide that was discovered in 1998 by two different
labs concurrently (de Lecea, Kilduff et al. 1998, Sakurai, Amemiya et al. 1998).
De Lecea and his colleagues reported that following tag PCR identification of
multiple mRNA sequences, one was specifically located within the lateral
hypothalamus (LH). Following cDNA isolation, they found that this prepro-peptide
encodes the mRNA sequence necessary for the production of two similar proteins,
specifically

in

the

LH.

Following

western

blot

analysis

as

well

as

immunohistochemistry, they discovered that the protein was indeed localized
within the LH. De Lecea named these neuropeptides hypocretins, due to their
position in the Hypothalamus, as well as their similarity to secretin (de Lecea,
Kilduff et al. 1998). Simultaneous research performed by Sakurai, who was
searching for potential ligands for receptors whose ligand specificity was still
unknown, found similar results and named the same proteins Orexin A (OXA) and
Orexin B (OXB), while their mRNA precursor was named prepro-orexin (Sakurai,
Amemiya et al. 1998). It was then discovered that the orexins carry out their
function through interaction with two GPCRs: Orexin Receptor 1 (OX1R) and
Orexin Receptor 2 (OX2R) (de Lecea, Kilduff et al. 1998, Sakurai, Amemiya et al.
1998). Despite similar properties, the two receptor types exhibit differing affinities.
While OX2R can bind with either OXA or OXB with nearly equal affinity between
subtypes, OX1R has a much higher affinity for OXA (Sakurai, Amemiya et al.
1998). Sakurai also found that, following ICV injection of OXA or OXB, food intake
increases in a dose dependent manner, and in a fasted state, prepro-orexin is
elevated in the LH, indicating an initial role for orexin in appetite (Sakurai,
Amemiya et al. 1998).
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Despite the initial idea that orexin primarily controls appetite regulation, it
was discovered that although orexin is only produced in the LH, its projections
reach multiple parts of the brain. Axonal projections from LH orexin neurons
reached important areas such as the hypothalamus, brain stem, limbic system, as
well as the circumventricular organs (Peyron, Tighe et al. 1998, Nambu, Sakurai
et al. 1999, Kilduff and Peyron 2000). Because of its extensive projections
throughout the brain, orexin has been implicated in multiple physiological
processes such as sleep (Kilduff and Peyron 2000), arousal, appetite (Sakurai,
Amemiya et al. 1998), and in recent years, regulation of blood pressure and
sympathetic outflow (Li, Hindmarch et al. 2013, Li and Nattie 2014) (Fig. 1.4).

Figure 1.4: Although orexin production only occurs within neurons located in the
Lateral Hypothalamus, vast axonal projections to other brain areas allow orexin to
carry out functions in multiple physiological processes.
1.7.1 Orexin Effect on Blood Pressure
Many orexin projections from the LH reach important cardiovascular
regulatory areas, indicating the potential for orexin action on cardiovascular
function. Along with the localized orexin neurons far reaching axonal projections,
many of the areas of innervation coincide with concentration of both OX1R and
OX2R in these cardiorespiratory areas. Similar to the OX projections, OX1R and
OX2R mRNA, the precursor to protein formation, are present in areas of the
21

hypothalamus such as the PVN, in Sprague Dawley rats (Trivedi, Yu et al. 1998,
Li and Nattie 2014), as well as areas of SNA control such as the NTS (Marcus,
Aschkenasi et al. 2001, Li and Nattie 2014). OX1R and OX2R containing cell
bodies were also found to be localized in similar areas (Li and Nattie 2014).
Because of the co-localization of both orexin hypothalamic neuron
projections and their receptors in major cardiovascular areas of the brain,
researchers began to study the potential effect of orexin on cardiovascular
regulation. Samson et al. found that upon ICV administration of OXA and OXB in
doses of 1 and 5 nmol in normal conscious SD rats, mean arterial pressure
significantly increased in a dose dependent manner (Samson, Gosnell et al.
1999). Interestingly, these reported increases in MAP were similar to those elicited
by ICV injection of 0.1 nmol ANGII under the same conditions (Samson, Gosnell
et al. 1999). Following the established role of orexin in blood pressure regulation,
electrophysiological recording showed that administration of OXA and OXB to
primary neuron cultures of the PVN and RVLM elicited dose dependent
depolarization of the neurons, a response that was effectively mitigated following
administration of both OX1R and OX2R antagonists together (Shirasaka,
Miyahara et al. 2001, Huang, Dai et al. 2010).
Further studies in rats showed that lack of orexin function following genetic
prepro-orexin knockout showed that normal rats lacking the prepro-orexin gene
exhibited a significantly lower resting blood pressure when compared to their
normotensive wild-type littermates (Schwimmer, Stauss et al. 2010). Similar to
Samson et al., others found that central administration of both orexins via ICV in
rats elicited a dose dependent response in not only MAP, but also SNA outflow in
conscious and anaesthetized animals alike (Shirasaka, Nakazato et al. 1999, Li
and Nattie 2014). However, since the lateral ventricles allow the orexin to diffuse
to various brain areas, it makes it hard to pinpoint an exact area of orexin influence
on SNA outflow and cardiovascular influence. More localized microinjections of
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OXA in varying doses into the RVLM of SD rats showed a significant increase in
both SNA as well as MAP (Shahid, Rahman et al. 2012), and this response was
attenuated following prior administration of an OX1R antagonist (Shahid, Rahman
et al. 2012). The combination of these studies outlines the extensive role that
orexin plays, when administered exogenously, in various parts of the brain,
leading many researchers to believe that orexin system dysfunction may play a
role in the development and maintenance of hypertension.
In BPH/2J mice, a model for essential hypertension, Marques et al.
(Marques, Campain et al. 2011) found that there is an increase in the gene that
encodes for orexin within the hypothalamus of these mice when compared to
controls in both early and established hypertension (Marques, Campain et al.
2011, Marques, Campain et al. 2011), indicating an intrinsically higher orexin
activity in the hypothalamus of rat models of primary hypertension. Similar studies
were then carried out in Spontaneously Hypertensive Rats (SHR), a commonly
used rat model of primary/neurogenic hypertension that mimics age related
progression of hypertension development often observed in humans. Li et al.
found that decreasing orexin activity through oral administration of almorexant, a
dual orexin receptor antagonist, resulted in a decrease in blood pressure of
approximately 30mmHg in SHR (Li, Hindmarch et al. 2013). The same study
showed a large increase in RVLM orexin mRNA expression, although this finding
did not reach statistical significance (Li, Hindmarch et al. 2013). A subsequent
study concerned with the specific effects of OX2R found that upon central
blockade of OX2R function via ICV of an OX2R antagonist as well as
microinjection into the RVLM of SHR caused a significant decrease in blood
pressure as well as HR (Lee, Dai et al. 2013), but found a decrease in RVLM
OX2R expression, in opposition to previous studies. A follow-up study performed
by the same group showed an increase in hypothalamic OXA and OXB as well as
RVLM OXA in SHR compared to WKY rats (Lee, Tsai et al. 2015), and also used
retrograde labelling to discover that SHR have more orexin projections to the
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RVLM than do WKY rats (Lee, Tsai et al. 2015). Further immunohistochemical
studies in SHR and normal Wistar Kyoto (WKY) rats showed that SHR showed a
greater number of orexin expressing neurons in the medial hypothalamus
compared to WKY rats (Clifford, Dampney et al. 2015), indicating that central
orexin system overactivation may exacerbate or potentially be a cause for
neurogenic hypertension observed in the SHR.
1.7.2 Orexin in Salt Sensitive Hypertension
Despite the importance of orexin function in the regulation of blood pressure
as well as in the pathology of hypertensive animal strains such as the BPH/2J
mouse and SHR, little is known about the implications of orexin in SSH. However,
there is evidence that the orexin system directly impacts the pathogenesis of SSH.
It has been extensively reviewed and established that increased SNA as well as
RAAS activity and subsequent AVP release are essential to the development of
SSH in both DOCA and Dahl S rats, two models of SSH (de Champlain, Krakoff
et al. 1968, Berecek, Barron et al. 1982, Gordon and Mark 1983, Gordon and
Mark 1984, Victor, Morgan et al. 1986, Gutkind, Kurihara et al. 1988, Yang, Jin et
al. 1992). Exogenous orexin administration in normotensive rats has also been
shown to cause a drastic increase in blood pressure (Shirasaka, Nakazato et al.
1999, Li and Nattie 2014), while orexin knockdown via differing mechanisms such
as oral or central receptor blockade as well as genetic manipulations of preproorexin activity mitigate the increase in blood pressure (Schwimmer, Stauss et al.
2010, Lee, Dai et al. 2013, Li, Hindmarch et al. 2013). In addition, orexin has been
shown to play a role in the SHR and the development of hypertension.
Implications for mediation of SSH through the PVN specifically through AVP
production and secretion have been developed. AVP within the PVN following salt
loading has been shown to increase blood pressure as well as SNA in SSH
(Ribeiro, Panizza Hdo et al. 2015). Recent research done on Dahl-S rats fed a HS
diet has shown that PVN orexin signaling effects the development of hypertension
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in this salt sensitive model (Huber, Fan et al. 2017). Polymerase Chain Reaction
(PCR) studies conducted on the PVN of Dahl S rats following a HS diet show that
mRNA levels of OX1R, OX2R, as well as AVP are all significantly increased in
Dahl S rats fed a HS diet when compared to their normal salt counterparts (Huber,
Fan et al. 2017), while immunostaining showed a greater concentration of OX1R
overexpression in the PVN following HS intake. The same study shows that, in
primary hypothalamic cultures, AVP mRNA is increased in a dose dependent
manner following incubation in OXA, and this effect is diminished following
application of an OX1R antagonist (Huber, Fan et al. 2017). Furthermore, PVN
OX1R blockade following microinjection decreased the elevated BP normally
observed in this model (Huber, Fan et al. 2017). This data indicates the essential
role that orexin, specifically OXA and its interaction with OX1R, plays in the
maintenance of SSH in the Dahl S rat through modulation of AVP release and
SNA outflow.
Despite the implications for orexin system over-activation in the
pathogenesis of Dahl Salt Sensitive SSH, there is no data addressing its potential
role for it in other SSH models, specifically the DOCA rat. To date, only one paper
has been published concerning orexin activity in the DOCA model. However, this
paper was primarily concerned with diurnal influences on orexin function in DOCAsalt hypertension (Hernandez, Watkins et al. 2018). In this study, they found that
OX1R, OX2R, and OXA are increased within the hypothalamus following DOCA
Salt treatment (Hernandez, Watkins et al. 2018). However, many questions
remain concerning the role of the orexin system in the DOCA rat model, and other
salt sensitive models of hypertension.

1.8 Hypothesis
In both Dahl S and DOCA rats, AVP is a primary influence on the development
and maintenance of hypertension (Berecek, Barron et al. 1982, Berecek, Murray
et al. 1982, Schenk and McNeill 1992, Huber, Fan et al. 2017) . AVP is primarily
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produced within the PVN and SON (Treschan and Peters 2006). The PVN is also
an area of integration of blood osmolality signals through projections stemming
from the CVOs (Sunn, McKinley et al. 2003, Pan 2004). Upon HS intake, AVP is
upregulated in the PVN, an area of major cardiovascular integration within the
brain. Orexin system over activation has been implicated in primary hypertension
development in both BPH/2J mice (Marques, Campain et al. 2011) as well as SHR
(Li, Hindmarch et al. 2013). Ablation of orexin function both centrally and through
peripheral means has been shown to cause a decrease in the normal elevation of
BP (Schwimmer, Stauss et al. 2010, Lee, Dai et al. 2013, Li, Hindmarch et al.
2013). Furthermore, OXA has been shown to directly affect SSH in the Dahl S rat
model following HS intake, specifically through interaction with the OX1R within
the PVN, and subsequent release of AVP to the periphery (Huber, Fan et al.
2017). Lastly, the only study concerned with orexin function in the DOCA rat model
shows an increase in OXA as well as OX2R within the hypothalamus following
DOCA-HS treatment. However, this study does not observe the PVN specifically,
nor does it directly address the effects that the orexin system may play on the
development of hypertension (Hernandez, Watkins et al. 2018).
Due to this evidence for orexin function in SSH development, we hypothesize
that, following DOCA-HS treatment in SD rats, the DOCA pellet induced renal
sodium and water reabsorption, as well as HS intake will cause PVN OX1R
signaling to be upregulated via projections of osmoreceptors detecting blood
osmolality from the CVOs. We also hypothesize that OXA projections to the PVN,
as well as cell body concentration within the LH will be increased in the DOCA
rats. Following the interaction between OXA and OX1R in the PVN, we believe an
increased AVP production and subsequent secretion into peripheral circulation
will cause an increase in both vasoconstriction as well as water reabsorption
within the kidneys, resulting in an increased blood volume, and resultant
hypertension. Furthermore, we hypothesize that PVN microinjection of AAV2OX1R-shRNA, a virus causing downregulation of OX1R, will result in a decrease
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in OX1R activation and AVP release from the PVN, as well as decreased plasma
AVP and levels. We believe that reducing OX1R function within the PVN of DOCA
rats will alleviate, at least in part, the development of hypertension in this model.
A visual representation of our hypothesis can be observed in figure 1.5. The
results of this study may offer insight into the role of orexin in SSH, and may
produce evidence offering a new potential pharmaceutical target for hypertension
treatment.

Figure 1.5: Representative model of the hypothesized mechanism underlying
orexin control of blood pressure in the DOCA-rat model. Circumventricular organs
(CVO), lateral hypothalamus (LH), paraventricular nucleus (PVN), orexin A (OXA),
orexin-1 receptor (OX1R), arginine vasopressin (AVP), adeno-associated virus –
OX1RshRNA (AAV2-OX1R-shRNA).
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2 Methods
2.1 Animals
All animal breeding was performed and overseen by our lab with the help of
the Animal Care Facility (ACF). Adult male rats (200-350g) were placed into three
groups: DOCA-Salt, DOCA-Salt + OX1RshRNA, or untreated control. The DOCASalt group received implantation of a 21-day release DOCA pellet (75mg,
Innovative Research of America, FL, USA), and saline drinking solution (1% NaCl
and 0.2% KCl) with normal chow for 21 days. DOCA-Salt + OX1RshRNA rats
received a PVN microinjection of AAV2-OX1R-shRNA (University of Florida) two
weeks prior to DOCA and high salt diet administration, identical to the DOCA-Salt
group. The untreated controls were given sham surgeries, and normal water and
chow. During the 3 weeks, blood pressure measurements were taken on DOCASalt, DOCA-Salt + OX1RshRNA, and control rats. At the end of the three-week
DOCA release, rats were placed in metabolic cages for 3 consecutive days.
Following this, rats were euthanized and used for PCR, immunostaining, plasma,
and heart weight measurements. The time of euthanization was confined to early
afternoon, between approximately 2:00-5:00pm, in order to mitigate the chance of
any variability in measured physiological parameters due to the natural
fluctuations of orexin activity throughout the day. All rats were housed at a
constant temperature and a 12:12 hour light dark cycle, and given their respective
diets ad libitum. All animal experiments were performed in adherence to protocols
approved by the Michigan Technological University Institutional Animal Care and
Use Committee (IACUC).

2.2 Hypothalamic Paraventricular Nucleus Microinjections
Prior to any diet or DOCA treatment, DOCA-Salt + OX1RshRNA rats were
subjected to bilateral PVN microinjection of AAV2-OX1R-shRNA, a viral vector
that carries a small hairpin RNA that specifically targets the gene encoding for
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OX1R, effectively knocking down OX1R function. Rats were anaesthetized using
5% isoflurane for induction, and 2-3% isoflurane exposure for maintenance of
anesthesia. Following complete anesthesia, rat heads were fixed in a stereotaxic
frame, so that bregma and lambda were level with one another. Two holes were
drilled through the skull at coordinates of the PVN so that a single glass
microinjector pipette could be lowered into the PVN area. The coordinates for the
PVN (in mm) were as follows: -1.6 caudal to bregma, 0.5-0.7 lateral to the midline,
and 7.2 deep. Once the microinjector was in place, 200 nl of AAV2-OX1R-shRNA
was injected bilaterally into the PVN. Approximately 10-12 minutes was taken
between injections to allow for diffusion of the viral vector. Following injection, the
wound was sutured, and rats were given a subcutaneous injection of a cocktail
solution of meloxicam, penicillin, and sterile 0.9% saline the day of injection, as
well as two days after in accordance with IACUC and ACF standards. DOCA-Salt
OX1RshRNA rats were given 2 weeks to recover as well as to allow full viral
expression, before any other procedures were performed.

2.3 DOCA Pellet Implantation
DOCA-Salt and DOCA-Salt + OX1RshRNA groups were subjected to
subcutaneous implantation of a DOCA pellet (75mg, 21-day release, Innovative
Research of America, FL, USA) prior to beginning the high salt drink treatment.
Rats were given 5% isoflurane for anesthesia induction followed by 2-3%
isoflurane to maintain adequate anesthesia during the procedure. A subcutaneous
incision was made in the retro-scapular region, and the DOCA pellet was placed
under this layer. The wound was sutured, and rats were given the same postoperative care as above. However, directly following the procedure, all rats’
drinking water was switched to a saline solution (1%NaCl and 0.2%KCl) for the
remainder of the 21 days. As previously mentioned, DOCA treatment is usually
paired with uninephrectomy to exacerbate the development of hypertension.
However, we decided to exclude the kidney removal following a previously
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established model (Kandlikar and Fink 2011) to obtain a more gradual progression
of hypertension development that more closely mimics that seen in a humans, as
well as to eliminate many of the adverse effects that kidney removal has, and their
causative effects on hypertension (Kandlikar and Fink 2011). This allows us to
more confidently assume that any results from this study occur because of the
DOCA pellet and high salt administration and its interaction with the orexin
system.

2.4 Blood Pressure Measurement
A subset of each group was subjected to blood pressure measurement
during their treatment period using tail plethysmography (Kent Scientific, CT,
USA). DOCA-Salt, DOCA-Salt +OX1R-shRNA, and control rats were all
acclimated to the procedure for a week before measurements began through
everyday blood pressure measurements. Briefly, rats were placed in a plastic
cylinder with a dark nose-cone, to reduce vision and anxiety. After 10 minutes
acclimation, the tail cuff apparatus including the occlusion cuff and volume
pressure recording cuff were placed on the animal for an additional 5-10 minutes.
Artificial heating was also applied to maintain adequate blood flow to the tail.
Following this, blood pressure recording began, and 10 acclimation cycles
followed by 20 measurement cycles were conducted. Following blood pressure
recording, averages of the 20 measurement cycles were taken and paired with
their group to obtain a group mean, which was reported. Rats maintained
acclimation during the 18-day treatment by daily 20-minute sessions in the rat
holder/tail cuff apparatus for every rat, to reduce variability and anxiety among the
rats.
Tail-cuff plethysmography can be attributed to stress-related fluctuations in
blood pressure, due to confinement in a small cylinder for extended periods of
time, which may lead to variability of results. However, all necessary precautions
were taken to mitigate this effect. Namely, acclimation to the cylinders as well as
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the occlusion/volume pressure recording apparatus began two weeks prior to any
actual blood pressure recording was performed. Following one week of
acclimation, blood pressure measurements were taken to identify when the blood
pressure reached a normotensive level in all treatment groups. Once the blood
pressure appeared to maintain a consistent, normotensive pressure, the
experiment was initiated. In addition, blood pressure recording sessions were
done during the same time every day (12:00-4:00pm), to mitigate circadian
influences on orexin system function, and thus to alleviate any fluctuations in
blood pressure that may naturally occur with differential orexin system activity
throughout the day. Furthermore, during the three weeks of blood pressure
recording, acclimation was maintained on days when blood pressure
measurements were not taken by daily exposure to both confinement in the
cylinder as well as attachment of the occlusion/volume pressure recording
apparatus for 20 minutes. A diagrammatic representation of this process can be
observed below (Fig. 2.1):

Figure 2.1: Representation of Tail-Cuff Plethysmography procedural acclimation
and subsequent BP measurements. Two weeks of acclimation were performed
before BP measurements were measured, mitigating any stress-induced
variability caused by the recording.

2.5 Metabolic Measurements
During the last 3 days of treatment, DOCA-Salt, DOCA-Salt + OX1RshRNA,
and control rats were placed in metabolic cages, where food and water intake, as
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well as urine and fecal output were measured. The first day in the metabolic cages
was discarded as the results were likely to be affected by the new change of
environment for the rats. Body weights were also taken weekly for all rats.
Following euthanization, hearts were removed and weighed, and presented as a
heart weight to body weight ratio (HW:BW).

2.6 Real Time PCR and Immunostaining
Following three weeks of treatment, rats were euthanized and subjected to
either real time polymerase chain reaction (PCR) analysis to observe mRNA
levels or immunostaining to visualize protein levels. For PCR, brains were
removed and immediately flash frozen in liquid nitrogen to mitigate RNAse activity.
Following flash freezing, all brains were placed into a -80 degrees Celsius freezer,
where they would remain until needed for mRNA analysis. Upon removal from the
freezer, the PVN area was punched. RNA isolation was performed using RNeasy
plus Mini kits (Qiagen, CA, USA) following packaged instructions. Following
isolation, the RNA was converted to complementary DNA (cDNA) using iScript
cDNA synthesis kits (Bio-Rad), and cDNA was used as a template for real time
PCR, which was performed to analyze mRNA levels of OXA, OX1R, and AVP
using gene specific Taqman primers and probes. The results were normalized to
mRNA expression of the housekeeping gene, GAPDH.
Immunostaining was used to analyze OX1R, OXA, and AVP protein
expression within the PVN, as well as OXA within the lateral hypothalamus. 20μm coronal brain sections containing the PVN or LH using the following
procedure. Rats were anesthetized under heavy isoflurane. Once under deep
anesthesia,

cold

phosphate

buffer

saline

(1xPBS)

followed

by

4%

paraformaldehyde (PFA) in 1xPBS was used to transcardially perfuse the animal.
Following perfusion, the brain was removed and kept in 4% PFA overnight in 4°C.
The next day, the brains were transferred and kept at 4°C in 30% sucrose until
they sank to the bottom. They were then cut in 20-μm coronal sections using a
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cryostat. Areas containing the PVN area as well as the LH were then subjected to
immunostaining. Following wash in 1xPBS 3 times for 10 minutes each, brain
sections were incubated with either rabbit anti-OX1R antibody (Alomon
Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (1:400
dilution), or mouse anti-OXA antibody (1:300 dilution) in PBS containing 0.5%
Triton X-100 and 5% horse serum for 4 days at 4°C. Following this incubation and
1xPBS washing, they were incubated overnight in secondary antibodies Alexa
fluor 488 goat anti rabbit IgG (1:500), Alexa fluor 594 goat anti rabbit IgG (1:500),
or Alexa fluor 594 donkey anti mouse IgG (1:500). Images representing
immunofluorescence were taken with a Leica DMIL microscope.

2.7 Plasma AVP and CSF Orexin A ELISA Testing
Rats were placed under heavy anesthesia using 5% isoflurane. They were
then decapitated, and blood was collected in tubes coated with 5.4mg EDTA (BD
Vacutainer, NJ, USA) to collect plasma for measurement. These tubes were then
centrifuged at 4°C using an Eppendorf 5804 R Centrifuge at 1300 RPM for 35
minutes. The supernatant was extracted, and stored in -80ºC until use. ELISA
testing was used to analyze both plasma concentration of AVP (Arg8-Vasopressin
Kit, Enzo Life Sciences, NY, USA) as well as cerebrospinal fluid Orexin A
concentrations

(Orexin-A

ELISA,

Fujuifilm,

Tokyo,

Japan)

using

the

manufacturer’s provided instructions.

2.8 Intracerebroventricular Injections
Male adult SD rats were subjected to ICV injections of either saline control
or OXA (Sigma Aldrich, MO, USA). Rats were anesthetized under 5% isoflurane,
and maintained at 2-3% isoflurane. Rats were set up in a stereotaxic frame as in
PVN injections. A hole was made in the skull to allow penetration of a Hamilton
syringe into the left lateral ventricle. The coordinates for injection were as follows:
-0.8 mm caudal to bregma, 1.6 mm lateral to the midline, and 3.6 mm deep. For
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the ICV injection, saline (0.9%) control was injected at a volume of 4μl over the
course of 4 minutes on only one side. Rats that received OXA (2nmol) also
received 4μl over the course of 4 minutes. Approximately 10 minutes following
injection brain and plasma were collected and used for PCR as well as ELISA
testing.

2.9 Data Collection and Analysis
All rats subjected to PFA perfusion and subsequent immunostaining were
unable to be used for any physiological analysis other than protein
immunofluorescence staining. However, all other animals subjected to brain,
blood, and CSF collection were utilized for multiple tests, including PCR and
ELISA. Because of the overlap, and the multiple utilizations of one sample for
various tests, some discrepancies in sample size may be present. In general, an
arbitrary sample size of 4-5, which is normally observed in other experiments
performed in rodent models, was chosen as a goal for each treatment group,
although this was not always the case due to the additional accumulation of new
results on the same physiological parameters tested throughout the progression
of the project. Furthermore, results from multiple experiments (Fig. 2.2) were
combined over the course of the project when the same parameters were
measured. However, to simplify the number of rats subjected to immunostaining
as well PCR and ELISA, Fig. 2.2 shows a representation of the number of rats
subjected to each treatment, and what physiological parameters were eventually
measured, excluding the six rats used during the ICV injection. In addition, all
animals that were lost during surgery, before any measurements were taken, were
not recorded, and were simply replaced, eliminating any effect on sample size.
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Figure 2.2: Representative diagram showing the number of rats from each
experiment (Exp. 1-5) during the project and what physiological analysis was
performed on each. Note: Only rats during experiment 5 were subjected to blood
pressure measurements over the course of the three-week treatment.
All data is expressed as Mean ± SEM unless otherwise noted. Individual blood
pressure means were observed, and then combined with other subjects within
their given treatment group to find a group mean and SEM. To test significance
unpaired one-tailed and two-tailed T-tests, as well as One-way ANOVA testing
was performed using Graphpad Prism-6 software. If significance was found using
the ANOVA, a Tukey HSD test was performed. For blood pressure and heart rate
data, a two-way ordinary ANOVA was performed, and if significance was found,
a Tukey multiple comparison test was performed between time points. All values
with a P<0.05 were considered significant.

35

3 Results
The classic model for DOCA-salt hypertension generally utilizes kidney
removal (uninephrectomy) to exacerbate the development and severity of
hypertension in the animal. However, for our model, we chose to omit the kidney
removal, allowing a more gradual and moderate increase in blood pressure, which
more closely mimics hypertension development observed in humans. However,
kidney removal affects renin levels, and thus AVP secretion and RAAS activity. It
has been extensively shown that AVP secretion is essential to hypertension
development in the classical DOCA-salt model, so we first assessed whether our
model would produce adequate central AVP production, as well as parallel
increases in OX1R levels. Furthermore, we wished to observe whether central
AVP increases correlated with peripheral secretion in the plasma, using this as
evidence of downstream AVP activity on vasoconstriction and renal water
reabsorption. Lastly, we assessed metabolic measurements due to AVP and
orexin regulation of metabolic activity.

3.1 DOCA-salt Treatment Increases PVN AVP and OX1R
Expression
The efficacy of our modified DOCA-salt model in producing a similar
increase in central AVP production as the classical uninephrectomized DOCA-salt
rats was tested following 3-weeks of DOCA-salt treatment. Following treatment,
real time PCR was used to analyze PVN AVP mRNA expression, and
immunostaining was used to visualize AVP protein expression within the PVN.
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Figure 3.1: PVN AVP mRNA expression following 3-weeks of DOCA-salt
treatment. DOCA-salt (n=9) treatment significantly increased PVN AVP mRNA
expression compared to control rats (n=8). *P<0.05 using an unpaired two-tailed
T-test.
A significant increase in PVN AVP mRNA expression was observed in
DOCA-salt rats (n=9) when compared to control rats (n=8) (control: 1±0.319 vs.
DOCA-salt: 3.142±0.7914, P<0.05), which was to be expected, as it is generally
observed in the classic DOCA-salt model (Fig. 3.1). Further immunostaining
assessment also showed a large increase in PVN AVP protein expression when
compared to control rats (Fig. 3.2). The combination of these results shows that
DOCA-salt treatment results in significantly increased AVP production within the
PVN, inferring that overproduction of AVP is still present in our modified DOCAsalt model.

37

Figure 3.2: Representative immunostaining images of AVP protein expression in
control (left) and DOCA-salt (right) rats.
After observing an increase in central AVP production within the PVN of
DOCA-salt rats, we then analyzed whether an increase in OX1R receptor
expression occurs in parallel with PVN AVP increases following DOCA-salt
treatment. To assess this, PCR and immunostaining were once again utilized to
assess PVN mRNA and protein expression. PCR results indicated a significant
increase of approximately 23% in PVN OX1R mRNA levels following DOCA-salt
treatment (n=4) compared to control (n=3) (control: 1.00±0.049 vs. DOCA-salt:
1.231±0.08; P<0.05) (Fig. 3.3).
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Figure 3.3: PVN OX1R mRNA expression following 3-weeks of DOCA-salt
treatment. DOCA-salt (n=4) treatment significantly increased PVN OX1R mRNA
expression compared to control rats (n=3). *P<0.05 using an unpaired one-tail Ttest.
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To affirm whether increased OX1R mRNA levels resulted in increased OX1R
protein expression, immunostaining was performed. Immunostaining images
show a large increase in OX1R expression and concentration in the PVN area
(Fig. 3.4). The significant increase in both AVP as well as PVN OX1R expression
is indicative of a relationship between the parallel increase observed and DOCAsalt treatment.

Figure 3.4: Representative immunostaining images showing expression of the
orexin-1 receptor (OX1R) in the PVN in both control (left) and DOCA-salt (right)
rats. Third ventricle (3V).

3.2 DOCA-salt Treatment Increases Plasma AVP Concentration
The DOCA-salt model is generally characterized by elevated plasma AVP
concentrations. Since an increase in PVN AVP expression was expressed, we
used ELISA to test plasma AVP concentrations in control rats as well as DOCAsalt treated rats, to observe whether the central increase in AVP production results
in an increase in peripheral circulation. Following 3 weeks of treatment, DOCA39

salt treated rats (n=8) showed a significantly higher plasma AVP concentration
when compared to control rats (n=4) (control: 9.04±2.57 vs. DOCA-salt:
37.94±8.66 pg/ml; P<0.05) (Fig. 3.5). This result agrees with previous
observations showing similar increases in peripheral AVP levels (Lariviere, St-

*

50
40
30
20
10

S

0

D

O

C

C

o

n

A

tr

-H

o

l

A V P C o n c e n t r a t io n ( p g /m l)

Louis et al. 1988, Saravia, Grillo et al. 1999).

Figure 3.5: Plasma AVP concentrations (pg/ml) in control (n=4) and DOCA-HS
(n=8) treatment groups. DOCA-salt treatment resulted in a significant increase in
plasma AVP concentration. *P<0.05 vs. control using an unpaired two-tail T-test.

3.3 DOCA-salt Treatment Effects on Metabolism
Following 3 weeks of treatment, all rats were placed in metabolic cages for
72 hours to assess urine and fecal output, food and water intake, and body weight.
Following 24-48 hours of acclimation to the environment, food intake (g), fecal
output (g), water intake (mL), as well as urine output (mL) were measured over a
24-hour period to analyze the effects that our modified DOCA-salt model elicited
on metabolism.
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Figure 3.6: 24-hour metabolic data of control (n=4) and DOCA-salt (n=3) treated
rats following 3-weeks of treatment. DOCA-salt treatment significantly reduced
food intake when compared to control rats, but significantly increased water
intake, fecal output, and urine output when compared to control rats. *P<0.05,
**P<0.01, ****P<0.0001 vs. control using an unpaired two-tailed T-test.
Following 3-weeks of treatment, DOCA-salt rats (n=3) showed significant
differences in metabolism when compared to controls (n=4). DOCA-salt treatment
resulted in a significant decrease in food intake (control: 26.39±1.45 vs. DOCAsalt: 18.91±2.42 g, P<0.05), as well as a significant increase in fecal output
(control: 4.26±1.15 vs. DOCA-salt: 1.41±0.38 g, P<0.05) when compared to
control rats (n=4) (Fig. 3.6). Also, DOCA-salt treatment resulted in a significant
increase in water intake (control: 22.72±2.719 vs. DOCA-salt: 176.7±29.24 ml,
P<0.01) and urine output (control: 6.8±0.578 vs. DOCA-salt: 126.1±5.346 ml,
P<0.0001) compared to controls (Fig. 3.6). A decrease in weight gain was also
observed following DOCA-salt (n=7) treatment when compared to control rats
(n=6) (control: 129±6.429 vs. DOCA-salt: 81.71±8.626 g, P<0.01) (Fig. 3.7).
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Figure 3.7: Difference in body weight from beginning and end of treatment.
DOCA-salt (n=7) treatment results in a significant attenuation of weight gain
compared to control rats (n=6). **P<0.01 using an unpaired two-tailed T-test.

3.4 Central Orexin-A Administration Increases Plasma AVP
Concentration in Normal SD rats
Following affirmation that plasma AVP levels are indeed increased
following DOCA-salt treatment, we then wished to find out whether orexin system
activity was a primary regulator of AVP release peripherally. Previous research
done in our lab showed a significant increase in PVN AVP protein expression
following acute OXA ICV injection in normal rats (Huber, Fan et al. 2017). Because
centrally administered OXA results in increased PVN production of AVP, we then
tested whether central administration of OXA causes a parallel increase in AVP
secretion into peripheral circulation. To test this, six rats were given ICV injections
of either 0.9% saline (n=3) or OXA (2nmol) (n=3). Ten minutes following injection,
animals were sacrificed and plasma was collected for AVP ELISA measurement.
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Figure 3.8: Plasma AVP concentrations (pg/ml) following ICV injection of saline
(0.9%) (n=3) or OXA (2nmol) (n=3). OXA ICV elicited a noticeable increase in
AVP plasma levels, although this did not reach significance (P=0.08) when using
an unpaired one-tailed T-test.
Although significance was not reached (P=0.08), an obvious trend towards
significance was observed as OXA ICV (n=3) elicited an increase in plasma AVP
levels when compared to saline controls (n=3) (saline: 46.86±8.73 vs. OXA:
82.69±19.23 pg/ml) (Fig. 3.8). This relationship indicates that acute central
injection of the OX1R agonist, OXA, results in an increase in peripheral AVP
circulation, leading us to believe that long-term orexin system over-activation may
lead to a chronic increase in plasma AVP often observed in the DOCA-salt model.
All data collected has shown that DOCA-salt treatment increases not only
central and peripheral AVP expression, but also increases PVN OX1R
expression. Furthermore, acute injection of the OX1R agonist, OXA, results in a
near significant increase in peripheral AVP in the plasma. However, these results
do not prove an interaction between orexin system activation and regulation of
AVP release in the DOCA-salt model, nor do they give any insight into long-term
orexin mediated AVP release. To analyze the chronic impact of the orexin system
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on DOCA-salt hypertension, rats were given bilateral PVN injections of AAV2OX1R-shRNA, a viral vector carrying a short hairpin RNA that specifically targets
and knocks down the gene that encodes for OX1R, two-weeks prior to DOCA-salt
treatment.

3.5 Lateral Hypothalamic OXA Neuron Expression Remains
Elevated Following Chronic PVN OX1R Knockdown
To investigate the relative concentration of protein expression of orexin
related proteins, immunostaining was performed, which allows visualization of
target protein expression within the relevant brain regions.
We first chose to investigate whether orexin producing neuron expression
within the LH, as well as axonal projection density in the PVN is increased
following DOCA-salt treatment. To test this, following three weeks of DOCA-salt
treatment, animals were transcardially perfused with cold 4% PFA, and brains
were removed. Coronal sections of the brain were then taken in areas that
corresponded to positions of the LH and PVN. These sections were subjected to
immunostaining, specifically targeting OXA. Following DOCA-salt treatment, it
appears that OXA expressing cell bodies within the LH were increased when
compared to SD untreated control rats (Fig. 3.9A). Interestingly, there did not
appear to be any major differences between PVN axonal projections in the DOCAsalt rats when compared to the controls (Fig. 3.9B).
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Figure 3.9: Representative immunostaining images showing expression of
orexin-A (OXA) within (A) the lateral hypothalamus (LH) as well as (B) the
Paraventricular Nucleus of the Hypothalamus. The first column shows untreated
control rats. The second column shows DOCA pellet (75mg, 21-day release) and
high salt (1%NaCl/0.2%KCl) treated rats (DOCA-HS). The third column shows
rats that received prior orexin-1 receptor viral antagonist bilateral microinjection
into the PVN two weeks prior to the DOCA-salt treatment (OX1RshRNA).
A similar increase in OXA cell body expression within the LH can be
observed in rats that received AAV2-OX1R-shRNA (OX1R antagonist) prior to
DOCA-salt treatment (Fig. 3.9A) when compared to untreated controls. However,
in contrast to the DOCA-salt rats, PVN OXA axonal projections from the LH
appear to have a greater expression and density in rats who received bilateral
PVN OX1R antagonist injections (Fig. 3.9B).
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3.6 Chronic PVN
Expression

OX1R

Knockdown

Decreases

OX1R

The above results show that DOCA-HS treatment increases OXA neuron
cell body immunoreactivity, indicating an intrinsic increase in LH orexin production
and activity. However, we also wanted to see how the treatment would affect PVN
OX1R, the receptor for OXA, expression and immunoreactivity.
PCR analysis of the PVN area showed that OX1R mRNA expression is
increased by approximately 35% following DOCA-salt treatment (1.348±0.109;
n=10) when compared to control rats (1±0.087; n=7) (Fig. 3.10). However, PVN
OX1R

knockdown

significantly

decreases

OX1R

mRNA

expression

(0.8537±0.072; n=5) when compared to DOCA-salt treated rats (P<0.05) (Fig.
3.10), indicating that viral vector application to the PVN effectively reduces OX1R
function within the PVN to normal levels.
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Figure 3.10: PVN OX1R mRNA levels of expression normalized to GAPDH
expression. DOCA-salt treated rats (n=10) show an increase of approximately
34% PVN OX1R expression compared to control rats (n=7), and this increase is
significantly reduced following OX1R knockdown (n=5) (P<0.05) using a one-way
ANOVA and Tukey post-hoc analysis.
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Immunostaining analysis showed an increase in OX1R expression within
the PVN of DOCA-salt rats when compared to control rats (Fig. 3.11), in
agreement with our previous results (Fig. 3.4). We then wished to test whether
bilateral injection of AAV2-OX1R-shRNA into the PVN of DOCA-salt rats reduces
the density of OX1R within the PVN. As shown above, OX1R expression is
increased in the DOCA-salt rats when compared to the controls (Fig 3.4).
However, following injection of AAV2-OX1R-shRNA prior to DOCA-salt treatment,
OX1R expression is successfully knocked down in the PVN (Fig 3.11), as
evidenced by the lack of co-localization of OX1R and GFP expressing neurons.

Figure 3.11: Representative immunostaining images showing orexin-1 receptor
(OX1R) expression within the PVN of control (far left), DOCA-salt (middle left),
and DOCA-salt rats injected with AAV2-OX1R-shRNA into the PVN (middle right).
The farthest image on the right shows co-immunostaining of both OX1R as well
as green fluorescence protein (GFP) that is intrinsically present in the viral vector
used for OX1R knockdown. The lack of OX1R expression in areas of high GFP
expression is indicative of successful OX1R knockdown following viral vector
injection.

3.7 Chronic PVN OX1R Knockdown Reduces Central AVP
Production
The above combination of results showing an increase in PVN OX1R mRNA
and protein levels, as well as an increase in LH OXA protein expression indicate
over activation of the orexin system as a key component in the development of
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DOCA-salt hypertension. To test whether the decrease in OX1R function following
viral injection resulted in a parallel decrease in central AVP mRNA expression,
PVN tissue was punched and subjected to PCR assessment. PVN AVP mRNA
levels were significantly increased following DOCA-salt treatment when compared
to controls (control: 1±0.319 vs. DOCA-salt: 3.142±0.791, P<0.05) (Fig. 3.12).
However, following chronic knockdown of PVN OX1R, AVP mRNA levels were
significantly decreased when compared to DOCA-salt (DOCA-salt: 3.142±0.791
vs. DOCA-OX1RshRNA: 0.644±0.281, P<0.05) (Fig. 3.12). There was no
significant difference observed between control and DOCA-OX1RshRNA groups.
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Figure 3.12: PVN AVP mRNA levels of expression normalized to GAPDH
expression. DOCA-salt treated rats (n=10) have a significant increase in PVN AVP
expression when compared to control (n=7) (*P<0.05) as well as when compared
to DOCA-HS/OX1RshRNA (n=5) (*P<0.05) rats using a one-way ANOVA and
Tukey post-hoc analysis.
Knockdown of OX1R results in a decrease in mRNA levels of OX1R as well
as

AVP

within

the

PVN,

along

with

subsequent

OX1R

protein

immunofluorescence, indicating that the orexin system over activation can be
corrected via bilateral microinjection of an OX1R antagonist into the PVN of
DOCA-salt rats. We then wished to elucidate whether chronic OX1R knockdown
would result in a subsequent decrease in AVP protein expression within the PVN.
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Figure 3.13: Representative immunostaining images showing arginine
vasopressin (AVP) expression within the PVN of control (far left), DOCA-salt
(middle left), and DOCA-salt rats injected with AAV2-OX1R-shRNA into the PVN
(middle right). The farthest image on the right shows co-immunostaining of both
AVP as well as green fluorescence protein (GFP) that is present in the viral vector
used for OX1R knockdown. The lack of AVP expression in areas where GFP is
high is indicative of successful decrease in AVP expression following OX1R
knockdown.
AVP expression within the PVN was greatly increased in DOCA-salt rats
compared to control rats, as can be observed by increased density and brightness
of AVP expression following immunostaining (Fig. 3.13). However, prior
microinjection of an OX1R antagonist (AAV2-OX1R-shRNA) reduces the
increased AVP expression that is normally seen in DOCA-salt rats (Fig. 3.13).
This indicates strong evidence for orexin system modulation of AVP production
and subsequent release following a DOCA-salt treatment.

3.8 Chronic PVN OX1R Knockdown Decreases Plasma AVP
Concentration
After observing increases in mRNA and protein expression of both OX1R as
well as AVP within the PVN of DOCA-salt rats, and the attenuation of this following
chronic OX1R knockdown, we began to investigate peripheral circulation of AVP.
We wished to observe whether central OX1R knockdown results in lowered
plasma AVP levels. We hypothesized that OX1R PVN knockdown would
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significantly decrease plasma AVP concentrations when compared to DOCA-salt
treated rats.
To test the chronic effects of orexin system modulation of peripheral AVP
secretion, following three weeks of DOCA-salt treatment, plasma as well as CSF
were collected as previously outlined, and subjected to AVP and OXA ELISA
testing.

Figure 3.14: (A) Cerebrospinal fluid OXA concentration in control (n=5), DOCAHS (n=3), and DOCA HS-OX1RshRNA rats (n=3). DOCA-salt treatment reduced
circulating CSF OXA, and this is mitigated by PVN OX1R knockdown, although
this relationship did not reach significance (P=0.37). (B) Plasma AVP
concentration (pg/ml) in control (n=3), DOCA-salt (n=6), and DOCA HSOX1RshRNA (n=3) rats. DOCA-salt treated rats show an increased AVP plasma
concentration, but this did not reach significance (P=0.09). However, following
two-tailed t-test evaluation, we observed a significant decrease in plasma AVP
following chronic OX1R knockdown (*P<0.05) when compared to DOCA-salt
treatment using a one-way ANOVA and Tukey post-hoc analysis.
Interestingly, we observed an apparent decrease in CSF OXA
concentration in DOCA-salt treated rats (47.04±12.5 pg/ml; n=3) when compared
to both control (93.62±20.25 pg/ml; n=5) and DOCA-salt/OX1RshRNA
(104.6±44.34 pg/ml; n=3) rats (Fig. 3.14A). Although this observation did not
reach significance (P=0.37), further explanation of this result can be found in the
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discussion. Furthermore, there is a strong trend towards significance (P=0.09) in
the long-term increase of plasma AVP in DOCA-salt (258.9±19.5 pg/ml; n=5)
when compared to control (181.7±43.6 pg/ml; n=3) and DOCA-salt/OX1RshRNA
(167.2±29.8 pg/ml; n=3) (Fig. 3.14B). However, because the trend was very
strong, we decided to determine whether OX1R PVN knockdown significantly
effects plasma AVP levels when compared only to DOCA-salt treated rats.
Following two-tailed t-test evaluation of DOCA-salt and DOCA-HS/OX1RshRNA
rats, we found that the OX1RshRNA treatment significantly decreased plasma
AVP when compared solely to DOCA-salt treatment (P=0.035) (Fig. 3.14B). This
trend is indicative of long-term modulation of plasma AVP secretion by central
orexin system functioning.
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3.9 Chronic PVN OX1R Knockdown Effects on Metabolism

Figure 3.15: 24-hour metabolic analysis of food and water intake as well as urine
and fecal output in all rats at the end of their respective treatments. DOCA-salt
treatment results in a significant increase in both water intake and urine output
when compared to control rats, and chronic knockdown of OX1R does not appear
to alleviate this effect. Control (n=4), DOCA-salt (n=5), DOCA+OX1RshRNA
(n=6). *P<0.05 vs. control, **P<0.01 vs. control using a one-way ANOVA and
Tukey post-hoc analysis.
Metabolic measurements were taken following 3-weeks of DOCA-salt
treatment. Over the course of 24-hours at the end of the treatment, DOCA-salt
rats (n=5) experienced a significant increase in water intake when compared to
control rats (n=4) (DOCA-salt: 141.3±28.89 vs. control: 22.72±2.72mL, P<0.05),
as well as increased urine output (DOCA-salt: 101±17.81 vs. control:
6.8±0.578mL, P<0.01) (Fig. 3.15). This significant increase was also observed in
DOCA-OX1RshRNA rat (n=6) water intake (DOCA-OX1RshRNA: 122.1±24.43 vs
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control: 22.72±2.72mL, P<0.05) and urine output (DOCA-OX1RshRNA:
79.58±11.3 vs. control: 6.8±0.578mL, P<0.01) when compared to control rats
(Fig. 3.15). There was no observed statistical difference between DOCA-salt and
DOCA-OX1RshRNA water intake and urine output. Similarly, no significant
differences were observed in food intake (control: 26.39±1.455 vs. DOCA-salt:
21.62±2.129 vs. DOCA-OX1RshRNA: 24.32±0.699g, P=0.1) or fecal output
(control: 1.41±0.378 vs. DOCA-salt: 3.48±0.813 vs. DOCA-OX1RshRNA:
2.76±0.295g, P=0.07) between any of the groups (Fig. 3.15).
During the three-week treatment, body weight was taken once per week in
control (n=10), DOCA-salt (n=17), as well as DOCA+OX1RshRNA (n=5) groups.
We then assessed the difference in body weight from the beginning of treatment
and the day of euthanization. This allowed us to assess the affect that DOCA-salt
as well as DOCA-salt + OX1RshRNA may have on weight gain.
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Figure 3.16: Graph of the difference in weight between the beginning and end of
treatment in all groups. A significant dampening of weight gain is observed in both
DOCA-salt (n=17) as well as DOCA+OX1RshRNA (n=5) rats compared to
untreated controls (n=10). *P<0.05, and **P<0.01 vs. control using a one-way
ANOVA and Tukey post-hoc analysis.
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DOCA-Salt treatment caused a significantly lower weight gain over the
course of three weeks when compared to the control rats (control: 86±16.34 vs.
DOCA-salt: 53.06±7.54 g, P<0.01) (Fig. 3.16). DOCA-OX1RshRNA rats also had
a significantly lower weight gain than control rats (control: 86±16.34 vs. DOCAOX1RshRNA: 37.1±5.26 g, P<0.05) (Fig. 3.16). Although there was no significant
difference between DOCA-salt and DOCA+OX1RshRNA rats, there appears to
be a slight trend towards a greater attenuation of weight gain in OX1R knockdown
rats (Fig. 3.16).

3.10 Cardiac Hypertrophy is Partially Attenuated by PVN OX1R
Knockdown
Cardiac hypertrophy is often associated with hypertension development, and
may cause further cardiovascular dysfunction. To test cardiac hypertrophy, rat
hearts were removed and weighed following animal euthanization. Cardiac
hypertrophy was quantified by measuring the heart weight to body weight ratio
(HW:BW), which allows assessment of the percentage of the animal body weight
that is accounted for by the heart.
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Figure 3.17: Quantification of cardiac hypertrophy through measurement of heart
weight to body weight ratio (HW:BW). DOCA-salt (n=13) showed a significantly
increased heart size when compared to control rats (n=8). DOCA-OX1RshRNA
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(n=5) showed a slight decrease in HW:BW compared to DOCA-salt rats, but this
trend did not reach significance using a one-way ANOVA and Tukey post-hoc
analysis. *P<0.01 vs. control.
DOCA-salt rats (n=13) had a significantly higher HW:BW when compared
to control rats (n=8) (control: 0.311±0.011 vs. DOCA-salt: 0.402±0.017%,
P<0.01). DOCA-OX1RshRNA rats (DOCA-OX1RshRNA: 0.352±0.019%) showed
no significant differences when compared to either control or DOCA-salt rats,
although there is a slight decrease when compared to DOCA-Salt rats (DOCAOX1RshRNA: 0.352±0.019 vs. DOCA-salt: 0.402±0.017%, P>0.05) (Fig. 3.17),
indicating that OX1R knockdown may slightly alleviate the cardiac hypertrophy
observed in DOCA-salt hypertension, even though significance was not reached.

3.11 PVN OX1R Knockdown Attenuates Elevation of Blood
Pressure in DOCA-salt Rats
Because over activation of the orexin system in the PVN is observed in the
DOCA-salt model, and largely attenuated following PVN OX1R knockdown, as
well as AVP, we decided to analyze whether OX1R PVN knockdown alleviated
DOCA-salt hypertension development. Using tail-cuff plethysmography, rats were
acclimated to blood pressure measurement for one week prior to the start of the
study. Control (n=5), DOCA-salt (n=4), and DOCA-OX1RshRNA (n=4) were all
from the same litter and measurements were performed during the same time.
The last day of the acclimation period was used as the baseline blood pressure
measurement. Following acclimation, blood pressure and heart rate were taken
over the course of 18 days. We did not perform BP measurements the last 3 days
of treatment because the rats were in metabolic cages at this time, and transport
to and from the cages to take BP measurements may have skewed the
recordings. Also, to keep the rats acclimated, they were placed in the holders
every day for 20 minutes on days when recordings were not measured. This was
done to lower anxiety, and keep results consistent. Two rats, one from the DOCAsalt and one from the DOCA-OX1RshRNA, were removed from blood pressure
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and heart rate measurements due to illness resulting in lack of food and water
intake, as well as physical deformity and body weight loss, all of which are factors
that may affect AVP, orexin activity, among other physiological parameters.
Because of these physiological implications, they were excluded from
measurement.
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Figure 3.18: Mean arterial pressure (MAP) measurements over the course of 18
days as measured by tail-cuff plethysmography comparing control (n=5), DOCAsalt (n=4), and DOCA+OX1RshRNA (n=4) rats. Results are reported as group
averages during each measurement day. Dotted line indicates when DOCA-pellet
and HS diet were administered. *P<0.05, **P<0.001 vs. control. #P<0.05,
##P<0.01 vs. DOCA-salt using a two-way ANOVA and Tukey post-hoc analysis.
Approximately one week following DOCA implantation, the DOCA-salt
group MAP raised to a point significantly greater than the control group (P<0.05)
(Fig. 3.18). This significant increase was maintained throughout treatment for the
most part. Interestingly, PVN OX1R knockdown resulted in a significant, and
sustained decrease in MAP when compared to the DOCA-salt rats (Fig. 3.18).
There was no significant difference between control and DOCA+OX1RshRNA
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groups at any point during the treatment (Fig. 3.18). At the end of the treatment,
the final blood pressure measurements were as follows: control: 107.91±5.99 vs.
DOCA-salt: 142.43±7.73 vs. DOCA+OX1RshRNA: 115.69±8.23 mmHg. Although
there was a slight increase in DOCA-OX1RshRNA MAP, this was never a
significant increase compared to control rats, but was significantly lower than the
DOCA-salt group (P<0.01), indicating that OX1R knockdown within the PVN
alleviates, at least in part, DOCA-salt induced hypertension, effectively reducing
the normal MAP that is observed in DOCA-salt hypertension.
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Figure 3.19: Heart rate recordings taken in the same rats that received BP
measurements over the course of 18 days. The dotted line indicates beginning of
DOCA-pellet and HS administration. There were no significant differences in heart
rate between groups using a two-way ANOVA and Tukey post-hoc analysis.
Despite the change in blood pressure between groups, there were no
significant differences in heart rate (HR) between groups at any point during the
treatment (Fig. 3.19). At the end of the 18-day measurements, measured heart
rates were recorded as follows: controls (HR of 309.44±39.14 BPM), DOCA-salt
(350.44±16.76 BPM), and DOCA-OX1RshRNA (324.82±34.59 BPM).
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4 Discussion
Approximately one-third of adults in the United States have hypertension,
which puts them at a much higher risk for further cardiovascular events (Centers
for Disease and Prevention 2011), effectively increasing the likelihood of
premature death. Of that one-third of the population affected by hypertension, it is
estimated that slightly more than half of those individuals also have salt sensitive
hypertension (SSH) (Weinberger, Miller et al. 1986). However, despite
advancements in hypertension research, the exact mechanism underlying its
pathology has yet to be fully understood. Recently, the impact that central orexin
function has on blood pressure regulation in various hypertensive rat models has
been gaining attention (Schwimmer, Stauss et al. 2010, Lee, Dai et al. 2013, Li,
Hindmarch et al. 2013, Lee, Tsai et al. 2015), with even more recent research
observing the potential role of orexin signaling in SSH (Huber, Fan et al. 2017).
However, the potential role of orexin in the DOCA-salt rat, a model for saltsensitive hypertension and hyperaldosteronism, has not yet been studied. To our
knowledge, this is the first study conducted focused solely on the effect of orexin
system function on the development and maintenance of hypertension in this
model. Our study reports five major findings: I.) Expression of AVP and OX1R are
increased in the PVN of DOCA-salt rats, and these increases are attenuated
following prior PVN OX1R knockdown; II.) OXA expressing cells within the LH are
increased in both DOCA-salt and DOCA-OX1RshRNA rats, and their axonal
projections to the PVN are increased in the DOCA-OX1RshRNA rats; III.) Plasma
AVP is increased following DOCA-salt treatment as well as OXA ICV, but is
markedly decreased following PVN OX1R knockdown; IV.) Cardiac hypertrophy
is present in DOCA-salt rats, and is at least partially attenuated following OX1R
PVN knockdown; and lastly V.) The development of hypertension in DOCA-salt
rats can be significantly attenuated following PVN OX1R knockdown. The
combination of these results indicates a potential crucial role for central orexin
system functioning in salt sensitive hypertension models.
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The PVN is a major area of cardiovascular integration, making it critical to
proper blood pressure regulation (Pan 2004, Wei, Yu et al. 2009, Ribeiro, Panizza
Hdo et al. 2015). One of the primary mechanisms underlying PVN regulation of
blood pressure is the production and release of AVP from magnocellular neurons.
Upon stimulation from peripheral osmolality and pressure changes, the CVOs,
which lack a blood brain barrier, send afferent signals to the PVN, causing the
production and subsequent release of AVP to the posterior pituitary, which
releases it to peripheral circulation allowing it to cause both water reabsorption as
well as vasoconstriction (Sunn, McKinley et al. 2003, Pan 2004, Kawano and
Masuko 2010). Due to AVP’s established role in long term blood pressure
regulation, as well as the presence of elevated AVP in many human hypertensive
patients (Cowley, Cushman et al. 1981), RAAS activity, which can trigger AVP
release, has become a major target for pharmaceutical intervention (Jarari, Rao
et al. 2015). However, these pharmaceutical aids are not always effective, which
can lead to the development of further complications such as resistant
hypertension, making it important to find other forms of antihypertensive
treatment. Previous work within our lab has found that PVN orexin functioning
greatly influences both AVP release and subsequent sympathetic outflow in DahlS rats, a genetic model of primary hypertension (Huber, Fan et al. 2017). Because
AVP is essential to the development of DOCA-salt hypertension, we hypothesized
that central orexin system functioning may play a role in DOCA hypertension. In
agreement with numerous other studies (Grillo, Saravia et al. 1998, Pietranera,
Saravia et al. 2004), we found that mRNA and protein expression of AVP are
elevated within the brain of DOCA-salt rats, specifically in the PVN (Fig. 3.1 &
3.2). We also observed an increase in plasma AVP (Fig. 3.5), similar to other
studies (Saravia, Grillo et al. 1999). However, our study is novel in that it is the
first to report elevated OX1R within the PVN (Fig. 3.3 & 3.4), as well as OXA in
the LH (Fig. 3.9) following DOCA-salt treatment. This, combined with the
implications of orexin function in blood pressure regulation led us to believe that
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the over active orexin system in the DOCA model may contribute to the
development of hypertension in this model.
We then found that acute central administration of OXA resulted in a drastic
increase in plasma AVP (Fig. 3.8), showing central OXA action elicits a substantial
effect on AVP release from the neurohypophysis. We chose to determine the
effects that chronic knockdown of PVN OX1R may have on the development of
hypertension in SSH models, to discover the long-term impact orexin played on
both central as well as peripheral AVP circulation. To do this, we used an adenoassociated recombinant virus that specifically inhibits function of OX1R. Following
previous models in which central knockdown of orexin receptor function resulted
in attenuation of blood pressure increases (Shahid, Rahman et al. 2012, Lee, Dai
et al. 2013), we performed bilateral microinjections of AAV2-OX1R-shRNA into
the PVN of rats prior to DOCA pellet implantation. In agreement with our
hypothesis, we found that OX1R PVN knockdown significantly reduced PVN
OX1R and AVP mRNA (Fig. 3.10 & 3.12), as well as PVN OX1R and AVP protein
expression (Fig. 3.11 & 3.13). In addition, chronic OX1R knockdown blocked the
increase in plasma AVP induced by DOCA-salt treatment (Fig. 3.14B).
Furthermore, significant decreases in blood pressure were observed in both the
development and maintenance phases of DOCA-salt hypertension development
(Fig. 3.18).
Our results largely affirm our hypothesis that DOCA-pellet implantation
causes increased orexin release from the LH which causes excitation of PVN
magnocellular neurons through interaction with OX1R, which causes release of
AVP into the peripheral circulation, resulting in vasoconstriction and increased
blood volume, eventually leading to the development of hypertension. However,
one discrepancy was that OXA axonal projections appeared to be more dense
and over-active in the DOCA-OX1RshRNA rats, as opposed to the DOCA-salt
rats, who did not appear to have much difference compared to the control. In
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addition, although it was not significant, DOCA-salt rats also appeared to have a
lower CSF OXA concentration (Fig. 3.14A), which we did not expect. However,
this can be reasonably attributed to action of a feedback loop initiated through
OX1R knockdown. The lack of OXA binding to OX1R in the PVN would be sensed
and cause a greater input of axonal OXA to the PVN to try to elicit a response.
Since the OX1R receptors were increased and abundant in the DOCA-salt rats,
this same feedback loop may not have been initiated, although further studies
must be conducted to adequately explain this discrepancy. Another possible
explanation, more so for the decreased CSF OXA, is that the decrease of CSF
OXA is indicative of a greater number of bound OXA molecules, meaning a
greater increase of central orexin system function. Since the DOCAHS/OX1RshRNA rats had fewer active binding sites on OX1R, more OXA was left
unbound, unable to elicit its actions through binding with its receptor. It is important
to note that OXA immunoreactivity was however increased in both DOCA-salt as
well as DOCA-OX1RshRNA rats within the LH, meaning that despite OX1R
knockdown in the PVN, OXA production remained elevated due to the DOCA-salt
treatment. This potentially strengthens the argument that OXA production is
increased in SSH, and that the increase in PVN OXA axonal projections in the
DOCA-OX1RshRNA rats compared to the DOCA-salt can be contributed to
receptor availability. It also offers evidence that a potential method of hypertension
treatment to be explored is through modulation of central orexin receptor activity,
as opposed to the receptor ligands.
There are a few reasons why we chose to use a DOCA model for saltsensitive hypertension. Approximately 10-30% of individuals are resistant to
hypertensive drug treatment, such as ACE inhibitors and ANGII receptor
blockade, and are diagnosed with resistant hypertension (Calhoun, Jones et al.
2008, Lee, Dai et al. 2013, Sim, Bhandari et al. 2013). The DOCA model serves
the dual purpose of allowing us to observe how orexin functions in another salt
sensitive model, and more specifically allows us to accurately model
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hyperaldosteronism, which is the primary cause of resistant hypertension
(Mulatero, Rabbia et al. 2002, Eide, Torjesen et al. 2004, Viera and Neutze 2010).
Our findings show that there is potential for orexin involvement in DOCA-salt
hypertension development and maintenance due to increased presence and
heightened functioning of the central orexin system, specifically through
modulation of AVP production and release. We also chose to use a modified
model of DOCA-salt rats to undertake this project. Namely, we omitted
uninephrectomy from the protocol. We did this following a similar procedure that
had been previously done (Kandlikar and Fink 2011). Excluding the
uninephrectomy allows us to more accurately observe the direct effect that
manipulations to orexin system function within the PVN has on hypertension
development, without any adverse cardiovascular implications that kidney
removal incurs (Kandlikar and Fink 2011). We believe that this model allows us to
more closely mimic the development of human hypertension, which tends to occur
more gradually, as opposed to the drastic, immediate spike that occurs in
uninephrectomized rats. Lastly, since orexin function has been observed in
primary hypertensive models such as the SHR and Dahl-S rat strains, and now
has possible implications in the DOCA-salt model, this may point to an important
underlying role for orexin in numerous different types of hypertension, making it
more practical for human application.

4.1 Implications
Even with current hypertensive medications in use, the prevalence of
hypertension and cardiovascular disease remains high. Research has been
conducted that has evaluated the implications of orexin system function on blood
pressure regulation, as well as SSH. The present research project offers the only
look into the potential role for the orexin system in development and maintenance
of DOCA-salt hypertension, primarily aldosteronism, the primary cause of
resistant hypertension. This helps strengthen the notion that orexin is a major
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regulator of cardiovascular function, and may help lead to future, more efficient
pharmaceutical interventions targeting orexin function.

4.2 Limitations
A few limitations are present in this study. First, the use of tail-cuff
plethysmography instead of blood pressure radio telemetry transducer
implantation may have added more variability to the blood pressure recordings.
Stress induced blood pressure changes may occur due to confinement in the
plethysmography holder. However, careful consideration was taken when animals
were introduced and acclimated to the procedure. This included a week of
acclimation before even beginning the study, as well as daily acclimation to
maintain proper comfort in the tubes. Furthermore, the efficacy of tail-cuff
plethysmography has been adequately reviewed (Feng, Whitesall et al. 2008),
and the blood pressure measured by tail cuff plethysmography has been shown
to resemble that measured by the radio-telemetry transducer in undisturbed
animals (Wilde, Aubdool et al. 2017). With all of this in mind, we do recognize the
variability associated with tail-cuff plethysmography, but feel we have adequately
reduced stress-induced blood pressure changes through our meticulous
acclimation protocol.
We further recognize that, during PVN mRNA testing, punching of the PVN
is not exact. This means that some of the brain area surrounding the PVN area
may be subjected to mRNA assessment as well, which may dilute our results. It
is difficult to punch the PVN alone since it is such a small area, and for this reason,
some variability in mRNA levels may be present. However, when paired with the
use of protein immunostaining, the mRNA results become more reliable, since
parallel increases in gene expression as well as the proteins they encode for are
observed.
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Lastly, our project only used male rats, without any female groups. It has
been observed that testosterone plays a large role in the development of
hypertension, and that males are more likely to have elevated blood pressure in
both animals and humans alike. The findings of this research may not encompass
the effects of DOCA-salt or PVN OX1R knockdown on females. Similar studies
conducted using female rats will be the goal of future studies, as will the
differences in orexin system function and subsequent hypertensive tendencies
between male and female animals.
Future directions to build from this study may include more chronic
responses to OX1R knockdown in DOCA-salt rats, since most studies are only
conducted over the course of three weeks using this model. Also, we would like
to further study the peripheral effects of PVN OX1R knockdown in DOCA-salt rats,
namely on kidney and heart function. Lastly, we would like to provide evidence of
potential implications of orexin on adrenal gland dysfunction, which is essential to
the pathogenesis of DOCA-salt development.

4.3 Conclusion
In conclusion, the present study has shown that there is potential of DOCAsalt hypertension mediation through central orexin system functioning within the
PVN. DOCA-salt treatment caused a significant increase in mRNA levels of AVP
and OX1R within the PVN when compared to controls, and this increase was
reduced following OX1R PVN knockdown. Protein expression of AVP and OX1R
showed a similar pattern of increased expression in the PVN of DOCA-salt rats,
and attenuation in DOCA-OX1RshRNA rat. Plasma AVP was also significantly
increased following DOCA-salt treatment. In addition, central administration of
OXA via ICV injection caused a notable increase in plasma AVP. Chronic OX1R
PVN knockdown resulted in a large decrease in plasma AVP concentration
compared to DOCA-salt treated rats. Furthermore, DOCA-salt as well as DOCAOX1RshRNA had increased OXA production in the LH. Also, DOCA-salt rats
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showed increased cardiac hypertrophy, and this was partially attenuated by PVN
OX1R knockdown. Lastly, chronic OX1R knockdown within the PVN significantly
decreased the elevation in blood pressure that is commonly observed in DOCAsalt hypertension. The results of this study show evidence of orexin system
regulation of AVP production and release in the DOCA-rat model, and show that
knockdown of OX1R function within the PVN significantly reduces hypertension in
this rat model, offering a new potential mechanism underlying the development of
salt-sensitive hypertension.
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A

Raw Data

Table A.1: Raw data for 24-hr fecal output (g) following 3 weeks of treatment
in each group. Bolded values utilized in control vs. DOCA-salt analysis.
24-hr Fecal Output (grams)
Control

DOCA-salt

DOCA+OX1RshRNA

1.34

2.9

3.64

2.5

1.7

2.56

0.95

4.69

2.3

0.85

2.1

1.72

-

6

2.84

-

-

3.47

Table A.2: Raw data for 24-hr food intake (g) following 3 weeks of treatment
in each group. Bolded values utilized in control vs. DOCA-salt analysis.
24-hr Food Intake (grams)
Control

DOCA-salt

DOCA+OX1RshRNA

22.7

25.3

25.5

29.5

26.1

24.33

27.67

19.77

25.9

25.7

14.36

24.6

-

22.59

21.06

-

-

24.54

Table A.3: Raw data for 24-hr water intake (mL) following 3 weeks of
treatment in each group. Bolded values utilized in control vs. DOCA-salt
analysis.

24-hr Water Intake (mL)
Control

DOCA-salt

DOCA+OX1RshRNA

17.06

232.69

93.9

29.4

163.31

177.1

19.8

134.08

98.8
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24.6

56

55.1

-

120.54

94.58

-

-

213.15

Table A.4: Raw data for 24-hr urine output (mL) following 3 weeks of treatment
in each group. Bolded values utilized in control vs. DOCA-salt analysis.
24-hr Urine Output (mL)
Control

DOCA-salt

DOCA+OX1RshRNA

7.15

36.35

75.82

7.85

90.45

91.65

7.05

136.69

72.85

5.15

121.77

32.25

-

119.73

89.44

-

-

115.45

Table A.5: Raw data for body weight increase (g) over the course of 3 weeks
of treatment. Bolded values utilized in control vs. DOCA-salt analysis.
3-Week Change in Weight (g)
Control

DOCA-salt

DOCA-OX1RshRNA

116

59

57

141

74

36.5

148

74

27

140

52

30

111

98

35

118

110

-

62

105

-

47

36

-

50

27

-

29

39

-

-

58

-

-

63

-

77

-

22

-

-

33

-

-

24

-

-

10

-

-

18

-

Table A.6: Raw data for mRNA levels of AVP and OX1R normalized to
GAPDH expression in the PVN.
PVN AVP mRNA/GAPDH
Control

DOCA-Salt

DOCA-OX1RshRNA

0.29861

4.075012

0.116243

0.274243

1.604951

0.182224

2.985346

3.499776

0.559579

0.441796

4.777558

0.678754

0.984581

0.469435

1.682963

0.753647

0.392013

-

0.735716

5.654253

-

1.526056

6.808918

-

-

0.999359

-

PVN OX1R mRNA/GAPDH
Control

DOCA-Salt

0.963092

1.318004

0.939703

1.140277

1.096772

1.407982

-

1.056115
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PVN OX1R mRNA/GAPDH
Control

DOCA-Salt

DOCA-OX1RshRNA

1.265941

1.927575

0.946485

1.021909

1.18423

0.960295

0.703364

1.087205

0.574349

1.32161

1.474146

0.93185

0.948758

1.04782

0.855416

0.961832

1.088295

-

0.776586

1.172714

-

-

1.593106

-

-

1.875779

-

-

1.025059

-

Table A.7: Raw Data for plasma AVP concentration (pg/ml) using ELISA.
Plasma ELISA AVP Concentration (pg/ml)
Control

DOCA-salt

14.74292

4.202917

2.488958

7.873542

8.144792

32.37125

10.78833

30.225

-

46.2918

-

50.14979

-

54.72375

-

77.54875

Table A.8: Raw Data for plasma AVP concentration (pg/ml) following OXA
ICV using ELISA.
Plasma ELISA AVP Concentration (pg/ml)
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Saline (0.9%) ICV

OXA (2nmol) ICV

45.68792

106.2921

62.52958

44.58083

32.36083

97.18917

Table A.9: Raw data for CSF OXA concentration (pg/ml) using ELISA.
CSF ELISA OXA Concentration (pg/ml)
Control

DOCA-salt

DOCA HS/
OX1RshRNA

19.023

37.929

142.571

111.537

71.762

154.929

113.859

31.428

16.163

86.943

-

-

136.727

-

-

Table A.10: Raw data for Plasma AVP concentration (pg/ml) using
ELISA following chronic OX1R knockdown.
Plasma ELISA AVP Concentration (pg/ml)
Control

DOCA-salt

DOCA HS/
OX1RshRNA

104.6883

254.7879

137.4867

255.6463

253.6813

226.8013

184.8092

193.9575

137.1929

-

278.8671

-

-

313.2242

-

-

254.7879

-
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Table A.11: Raw data for heart weight to body weight ratio presented as
a percentage of body weight following 3 weeks of treatment in each group.
HW:BW (%)
Control

DOCA-salt

DOCA-OX1RshRNA

0.334

0.518

0.390331

0.349

0.498

0.406241

0.325

0.406

0.321127

0.337

0.438

0.320442

0.266055

0.394

0.321429

0.317073

0.460252

-

0.283333

0.402793

-

0.272959

0.362155

-

-

0.359694

-

-

0.35533

-

-

0.34359

-

-

0.344262

-

-

0.346405

-

Table A.12: Raw data for MAP (mmHg) for 3 weeks of treatment in each group.
MAP (mmHg)
Week

Measurement

Control

DOCA-salt

Point
Week 0

Week 1

Baseline

T1

DOCAOX1RshRNA

120.5

111.1818

116.6

105.4286

116.4545

101.7

125.5

120.8571

117.8276

112.8182

113.7778

111.8889

125.3571

-

-

121.375

125.3636

112.6

119.6154

132.875

105.6154
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T2

Week 2

T3

T4

Week 3

T5

115.6667

127.3636

118

119.375

126.625

113

100.5333

-

-

134.375

127.5

101.6667

107.333

158.75

94.58824

108.8571

138.111

117.25

127.375

116.1

122.25

106.9091

-

-

116.5556

136.1429

119.7778

115.6111

129.5

112.75

114.75

141.75

128.4286

118.5

127.5

122.75

118.9231

-

-

107.875

127.2

114.125

91.6

156.6154

120.1538

127.75

153

138.1

127.6364

134

112.3636

115.1667

-

-

100.25

141.5

96.625

90.14286

164.5

116.6154

112.2308

133.625

136.6667

125.6

130.0909

112.8889

111.333

-

-

Table A.13: Raw data for HR (BPM) for three weeks during treatment in
each group.
Heart Rate (BPM)
Week

Measurement

Control

Point

DOCA-salt

DOCAOX1RshRNA
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Week 0

Week 1

Baseline

T1

T2

Week 2

T3

T4

Week 3

T5

204

333

264

327.5714

180.5455

346.5

309.1875

418.5714

323.8966

314.7273

431.8889

176.222

372.6429

-

-

292.375

280.3636

221.5

414.9231

379.375

329.5769

193

399.4545

295.7143

447.75

360.375

195.75

418.6667

-

-

313.75

484.5

231.25

395.9524

402.625

290.7059

475.4286

308.444

339.4167

431.625

237.2

353.4167

353

-

-

402

385.2857

325.5556

370.5

355.0833

188.3333

193

379.25

397.0714

347.375

391.375

323

333.3846

-

-

248.875

378.1

352.125

277.2

327.8462

255.8462

352.58333

238.4

321.6

400.1818

323.4615

318.5455

121.8333

-

-

439.75

310.9286

227.75

217.4286

347.5

323.3077

279.6154

392.875

367.8889

351.4

350.4545

380.3333

259

-

-
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Statistical Analysis

Table B.1: Mean 24-hr fecal output in control and DOCA-salt groups.
Fecal Output (g)
Control

DOCA-salt

N

4

3

Mean

1.41

4.263

SD

0.7568

1.985

SEM

0.3784

1.146

Lower 95% CI

0.2058

-0.6669

Upper 95% CI

2.614

9.194

Table B.2: Mean 24-hr fecal output in control, DOCA-salt, and
DOCA-OX1RshRNA groups.
Fecal Output (g)
Control

DOCA-salt

OX1RshRNA

N

4

5

6

Mean

1.41

3.478

2.755

SD

0.7568

1.818

0.7236

SEM

0.3784

0.8131

0.2954

Lower 95% CI

0.2058

1.22

1.996

Upper 95% CI

2.614

5.736

3.514
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Table B.3: Mean 24-hr urine output in control and DOCA-salt treatment groups.
Urine Output (mL)
Control

DOCA-salt

N

4

3

Mean

6.8

126.1

SD

1.156

9.259

SEM

0.5781

5.346

Lower 95% CI

4.96

103.1

Upper 95% CI

8.64

149.1

Table B.4: Mean 24-hr urine output in control, DOCA-salt, and
DOCA-OX1RshRNA groups.
Urine Output (mL)
Control

DOCA-salt

OX1RshRNA

N

4

5

6

Mean

6.8

101

79.58

SD

1.156

39.83

27.67

SEM

0.5781

17.81

11.3

Lower 95% CI

4.96

51.54

50.54

Upper 95% CI

8.64

150.5

108.6

Table B.5: Mean 24-hr water intake in control and DOCA-salt treatment groups
Water Intake (mL)
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Control

DOCA-salt

N

4

3

Mean

22.72

176.7

SD

5.438

50.65

SEM

2.719

29.24

Lower 95% CI

14.06

50.87

Upper 95% CI

31.37

302.5

Table B.6: Mean 24-hr water intake in control, DOCA-salt, and
DOCA-OX1RshRNA groups.
Water Intake (mL)
Control

DOCA-salt

OX1RshRNA

N

4

5

6

Mean

22.72

141.3

122.1

SD

5.438

64.41

59.83

SEM

2.719

28.81

24.43

Lower 95% CI

14.06

61.35

59.31

Upper 95% CI

31.37

221.3

184.9

Table B.7: Mean 24-hr food intake in control and DOCA-salt treatment groups.
Food Intake (g)
N

Control

DOCA-salt

4

3

86

Mean

26.39

18.91

SD

2.91

4.182

SEM

1.455

2.415

Lower 95% CI

21.76

8.517

Upper 95% CI

31.02

29.3

Table B.8: Mean 24-hr food intake in control, DOCA-salt, and
DOCA-OX1RshRNA groups.
Food Intake (g)
Control

DOCA-salt

OX1RshRNA

N

4

5

6

Mean

26.39

21.62

24.32

SD

2.91

4.761

1.711

SEM

1.455

2.129

0.6986

Lower 95% CI

21.76

15.71

22.53

Upper 95% CI

31.02

27.54

26.12

Table B.9: Mean 3-week body weight increases in control and DOCAsalt treatment groups.
Body Weight Change (g)
Control

DOCA-salt

N

6

7

Mean

129

81.71

SD

15.75

22.82

87

SEM

6.429

8.626

Lower 95% CI

112.5

60.61

Upper 95% CI

145.5

102.8

Table B.10: Mean 3-week body weight increases in control, DOCA-salt,
and DOCA-OX1RshRNA groups.
Body Weight Change (g)
Control

DOCA-salt

OX1RshRNA

N

10

17

5

Mean

86

53.06

37.1

SD

54.2

31.08

11.76

SEM

16.34

7.539

5.259

Lower 95% CI

49.59

37.08

22.5

Upper 95% CI

122.4

69.04

51.7

Table B.11: Mean PVN AVP and OX1R mRNA expression normalized to
GAPDH.
PVN AVP mRNA/GAPDH
Control

DOCA-salt

OX1RshRNA

N

8

9

5

Mean

1

3.142

0.644

SD

0.9007

2.374

0.6284

SEM

0.3185

0.7914

0.281

88

Lower 95% CI

0.247

1.317

-0.1363

Upper 95% CI

1.753

4.967

1.424

PVN OX1R mRNA/GAPDH
Control

DOCA-salt

N

3

4

Mean

0.9999

1.231

SD

0.08474

0.1609

SEM

0.04893

0.08047

Lower 95% CI

0.7893

0.9745

Upper 95% CI

1.21

1.487

PVN OX1R mRNA/GAPDH
Control

DOCA-salt

OX1RshRNA

N

7

10

5

Mean

1

1.348

0.8537

SD

0.2297

0.3461

0.1613

SEM

0.08683

0.1094

0.07215

Lower 95% CI

0.7875

1.1

0.6534

Upper 95% CI

1.212

1.595

1.054

Table B.12: Mean plasma AVP Concentration (pg/ml) in control and DOCAsalt groups.
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Plasma ELISA AVP Concentration (pg/ml)
Control

DOCA-salt

N

4

8

Mean

9.041

37.94

SD

5.141

24.5

SEM

2.571

8.661

Lower 95% CI

0.8603

17.46

Upper 95% CI

17.22

58.42

Table B.13: Mean plasma AVP Concentration (pg/ml) following saline or
OXA ICV.
Plasma ELISA AVP Concentration (pg/ml)
Saline (0.9%) ICV

OXA (2nmol) ICV

N

3

3

Mean

46.86

82.69

SD

15.12

33.31

SEM

8.729

19.23

Lower 95% CI

9.303

-0.0679

Upper 95% CI

84.42

165.4

Table B.14: Mean CSF OXA concentration (pg/ml) in all groups.
CSF OXA Concentration (pg/ml)
Control

DOCA-salt

OX1RshRNA

N

5

3

3

Mean

93.62

47.04

104.6

SD

45.27

21.66

76.8

90

SEM

20.25

12.5

44.34

Lower 95% CI

37.41

-6.755

-86.22

Upper 95% CI

149.8

100.8

295.3

Table B.15: Mean Plasma AVP concentration (pg/ml) in all treatment groups.
Plasma AVP Concentration (pg/ml)
Control

DOCA-salt

OX1RshRNA

N

3

5

3

Mean

181.7

258.9

167.2

SD

75.53

43.62

51.65

SEM

43.61

19.51

29.82

Lower 95% CI

-5.903

204.7

38.85

Upper 95% CI

369.3

313.1

295.5

Table B.16: Mean heart weight to body weight ratio presented as percent
body weight in control, DOCA-salt, and DOCA-OX1RshRNA groups.
HW:BW (%)
Control

DOCA-salt

OX1RshRNA

N

4

5

6

Mean

0.3106

0.4022

0.3519

SD

0.03188

0.05974

0.04271

SEM

0.01127

0.01657

0.0191

Lower 95% CI

0.2839

0.3661

0.2989
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Upper 95% CI

0.3372

0.4383

0.4049

Table B.17: Mean MAP over the course of 3 weeks in control, DOCA-salt,
and OX1RshRNA rats.

DOCA-OX1RshRNA

DOCA-salt

Control

MAP (mmHg)
Base

T1

T2

T3

T4

T5

N

5

5

5

5

5

5

Mean

117.92

115.31

116.97

116.868

114.006

107.911

1

3

SD

8.682

8.519

12.953

1.806

15.130

13.395

SEM

3.883

3.810

5.793

0.808

6.766

5.990

N

4

4

4

4

4

4

Mean

115.56

128.05

135.115

133.723

142.704

142.429

7

7

SD

4.131

3.317

18.140

6.503

14.326

15.468

SEM

2.066

1.658

9.070

3.251

7.163

7.734

N

4

4

4

4

4

4

Mean

112.00

112.30

108.939

120.927

121.186

115.699

4

4

SD

7.331

5.091

12.975

6.526

11.759

16.454

SEM

3.665

2.545

6.488

3.263

5.880

8.227
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Table B.18: Mean heart rate over the course of 3 weeks in control, DOCAsalt, DOCA-OX1RshRNA rat groups.

Control

HR (BPM)
Base

T1

T2

T3

T4

T5

N

5

5

5

5

5

5

Mean

305.626

353.34

393.951

329.252

280.135

309.439

63.583

80.473

106.894

87.523

3
SD

62.041

107.70

DOCA-OX1RshRNA

DOCA-salt

2
SEM

27.745

48.166

28.435

35.989

47.804

39.141

N

4

4

4

4

4

4

Mean

341.001

354.89

358.192

377.749

316.952

350.440

2
SD

115.597

52.185

108.077

15.900

57.938

33.519

SEM

57.798

26.092

54.039

7.950

28.969

16.759

N

4

4

4

4

4

4

Mean

277.655

260.63

303.697

308.490

312.029

324.820

5
SD

76.055

62.517

55.273

87.151

40.407

69.189

SEM

38.027

31.259

27.636

43.576

20.204

34.594
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Table B.19: Unpaired two-tail t-test analysis of 24-hr fecal output between
control and DOCA-salt treatment groups.
Unpaired Two-Tail T-test – Fecal Output
P value

0.043

P value summary

*

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=2.697 df=5

Table B.20: One-way ANOVA analysis of 24-hr fecal output between all
treatment groups.
Fecal Output
ANOVA Summary
F

3.295

P-value

0.0724

R-square

0.3545

ANOVA Table

SS

DF

MS

Treatment

9.642

2

4.821

17.56

12

1.463

(Between
Columns)
Residual (Within
Columns)

94

Total

27.2

14

Table B.21: Unpaired two-tail analysis of 24-hr food intake between control
and DOCA-salt treatment groups.
Unpaired Two-Tail T-test – Food Intake
P value

0.0371

P value summary

*

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=2.820 df=5

Table B.22: One-way ANOVA analysis of 24-hr food intake between all groups.
Food Intake
ANOVA Summary
F

2.374

P-value

0.1353

R-square

0.2835

ANOVA Table

SS

DF

MS

Treatment

51.73

2

25.87

(Between
Columns)

95

Residual (Within

130.7

12

182.5

14

10.89

Columns)
Total

Table B.23: Unpaired two-tailed t-test analysis of 24-hr water intake
between control and DOCA
Unpaired Two-Tail T-test – Water Intake
P value

0.0015

P value summary

**

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=6.240 df=5

Table B.24: One-way ANOVA analysis of 24-hr water intake between groups,
as well as Tukey post-hoc analysis
Water Intake
ANOVA Summary
F

6.124

P-value

0.0147

R-square

0.5051

ANOVA Table

SS

DF

96

MS

Treatment

35302

2

17651

34584

12

2882

69886

14

(Between
Columns)
Residual (Within
Columns)
Total

Tukey

Mean Diff.

95% CI

Significant?

Summary

Control vs.

-118.6

-214.7 to -

Yes

*

Yes

*

No

ns

DOCA-salt
Control vs.

22.53
-99.39

-191.8 to -

OX1RshRNA
DOCA-salt vs.

6.940
19.22

-67.51 to

OX1RshRNA

105.9

Table B.25: Unpaired two-tail t-test analysis of 24-hr urine output between
control and DOCA-salt groups.
Unpaired Two-Tail T-test – Urine Output
P value

< 0.0001

P value summary

****

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed
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t, df

t=26.36 df=5

Table B.26: One-way ANOVA analysis of 24-hr urine output between groups,
as well as Tukey post-hoc analysis.
Urine Output
ANOVA Summary
F

12.51

P-value

0.0012

R-square

0.6758

ANOVA Table

SS

DF

MS

Treatment

21223

2

10612

10180

12

848.3

31403

14

(Between
Columns)
Residual (Within
Columns)
Total

Tukey

Mean Diff.

95% CI

Significant?

Summary

Control vs.

-94.2

-146.3 to -

Yes

**

DOCA-salt

42.07
98

Control vs.

-72.78

-122.9 to -

OX1RshRNA

Yes

**

No

ns

22.62

DOCA-salt vs.

21.42

-25.63 to

OX1RshRNA

68.47

Table B.27: Unpaired two-tail t-test analysis of 3-week weight gain
between control and DOCA-salt groups.
Unpaired Two-Tail T-test – Change in Body Weight
P value

0.0013

P value summary

**

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=4.266 df=11

Table B.28: One-way ANOVA analysis of 3-week weight gain as well as
HW:BW between groups, as well as Tukey post-hoc analysis.
Weight Gain
ANOVA Summary
F

6.843

P-value

0.0037

R-square

0.3206

ANOVA Table

SS

DF

99

MS

Treatment

16021

2

8011

33948

29

1171

49969

31

(Between
Columns)
Residual (Within
Columns)
Total

Tukey

Mean Diff.

95% CI

Significant?

Summary

Control vs.

43.14

9.467 to

Yes

**

Yes

*

No

ns

DOCA-salt
Control vs.

76.82
59.1

12.82 to

OX1RshRNA
DOCA-salt vs.

105.4
15.96

-27.03 to

OX1RshRNA

58.95

HW:BW
ANOVA Summary
F

8.547

P-value

0.0017

R-square

0.4263

100

ANOVA Table

SS

DF

MS

Treatment

0.04254

2

0.02127

0.05724

23

0.002489

0.09978

25

(Between
Columns)
Residual (Within
Columns)
Total

Tukey

Mean Diff.

95% CI

Significant?

Summary

Control vs.

-0.09164

-0.1478 to -

Yes

**

No

ns

No

ns

DOCA-salt
Control vs.

0.03550
-0.04136

OX1RshRNA
DOCA-salt

-0.1126 to
0.02986

0.05028

vs.

-0.01547 to
0.1160

OX1RshRNA

Table B.29: Unpaired two-tail, and one-tail t-test analysis of PVN AVP and
OX1R mRNA/GAPDG between groups.
Unpaired Two-Tail T-test – PVN AVP mRNA/GAPDH
P value

0.03
101

P value summary

*

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=2.397 df=15

Unpaired One-Tail T-test – PVN OX1R mRNA/GAPDH
P value

0.0383

P value summary

*

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

One-tailed

t, df

t=2.226 df=5

Table B.30: One-way ANOVA analysis of PVN AVP mRNA/GAPDG
between groups, as well as Tukey post-hoc analysis.
PVN AVP mRNA/GAPDH
ANOVA Summary
F

5.085

P value

0.017

R-square

0.3486

ANOVA Table

SS

DF

MS

Treatment

28.02

2

14.01

(Between
Columns)
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Residual (Within

52.35

19

80.37

21

2.755

Columns)
Total

Tukey

Mean Diff.

95% CI

Significant?

Summary

Control vs.

-2.142

-4.191 to -

Yes

*

DOCA-salt
Control vs.

0.09335
0.356

-2.048 to 2.760

No

ns

2.498

0.1464 to 4.850

Yes

*

OX1RshRNA
DOCA-salt
vs.
OX1RshRNA

Table B.31: One-way ANOVA analysis of PVN OX1R mRNA/GAPDH
between groups, as well as Tukey post-hoc analysis.
PVN OX1R mRNA/GAPDH
ANOVA Summary
F

6.168

P value

0.0086

R-square

0.3937
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ANOVA Table

SS

DF

MS

Treatment

0.9729

2

0.4865

1.499

19

0.07887

2.472

21

(Between
Columns)
Residual (Within
Columns)
Total

Tukey

Mean Diff.

95% CI

Significant?

Summary

Control vs.

-0.3476

-0.6992 to

No

ns

No

ns

Yes

*

DOCA-salt

0.004009

Control vs.

0.1463

OX1RshRNA

-0.2714 to
0.5641

DOCA-salt

0.4939

vs.

0.1031 to
0.8847

OX1RshRNA

Table B.32: Unpaired T-test of plasma AVP concentration between saline
and OXA ICV rats.
Unpaired One-Tail T-test – Saline ICV vs. OXA ICV Plasma AVP
P value

0.0825
104

P value summary

ns

Significantly different? (P < 0.05)

No

One- or two-tailed P value?

One-tailed

t, df

t=1.696 df=4

P value

0.0825

Table B.33: Unpaired T-test of plasma AVP concentration between control
and DOCA-salt rats.
Unpaired Two-Tailed T-test – Control vs. DOCA-salt Plasma AVP
P value

0.0457

P value summary

*

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=2.281 df=10

P value

0.0457

Table B.34: One-way ANOVA analysis of CSF OXA concentration (pg/ml).
CSF OXA Concentration
ANOVA Summary
F

1.114

P-value

0.3744

R-square

0.2178

ANOVA Table

SS

DF
105

MS

Treatment

5828

2

2914

20932

8

2616

26760

10

(Between
Columns)
Residual (Within
Columns)
Total

Table B.35: One-way ANOVA analysis of plasma AVP concentration (pg/
ml) following chronic OX1R knockdown
Plasma AVP Concentration (pg/ml)
ANOVA Summary
F

3.248

P-value

0.0928

R-square

0.4481

ANOVA Table

SS

DF

MS

Treatment

19776

2

9888

24356

8

3044

(Between
Columns)
Residual (Within
Columns)
106

Total

44131

10

Table B.36: Unpaired two-tail t-test of plasma AVP concentration between
DOCA-salt and DOCA-HS/OX1RshRNA rats.
Unpaired Two-Tailed T-test – DOCA-salt vs. DOCA-HS/OX1RshRNA
Plasma AVP
P value

0.0354

P value summary

*

Significantly different? (P < 0.05)

Yes

One- or two-tailed P value?

Two-tailed

t, df

t=2.704 df=6

P value

0.0354

Table B.37: Two-way ANOVA analysis of 3 week MAP between groups, as
well as Tukey post-hoc analysis.
MAP
ANOVA

%Total

P Value

P Value

Significant?

Summary

Variation

Interaction

12.98

0.1111

ns

No

Row Factor

5.927

0.1977

ns

No

Column Factor

34.25

< 0.0001

****

Yes

ANOVA Table

SS

DF

MS

P value

Interaction

2089

10

208.9

P = 0.1111

Summary

107

Row Factor

953.9

5

190.8

P = 0.1977

Column Factor

5512

2

2756

P < 0.0001

Residual

7540

60

125.7

Total

16094.9

77

MAP
Time

Tukey

Point

Base

Mean

Significant? Summary

Diff

Control vs. DOCA-

2.353

HS
Control vs.

DOCA-HS vs.

5.917

3.564

ns

-12.16 to

No

ns

-15.49 to

No

ns

No

ns

No

ns

22.61

-12.74

HS
Control vs.

No

23.99

DOCA+OX1RshRNA

Control vs. DOCA-

-15.72 to
20.42

DOCA+OX1RshRNA

T1

95% CI

-30.82 to
5.328

3.009

DOCA+OX1RshRNA

-15.06 to
21.08

108

DOCA-HS vs.

15.75

DOCA+OX1RshRNA

T2

Control vs. DOCA-

-18.15

8.031

Control vs. DOCA-

26.18

-16.86

-4.059

Control vs. DOCA-

12.8

No

ns

7.127 to

Yes

**

-34.93 to

No

ns

-22.13 to

No

ns

-6.253 to

No

ns

Yes

***

No

ns

31.85

-28.7

HS
Control vs.

-10.04 to

14.01

DOCA+OX1RshRNA

T4

*

1.217

DOCA+OX1RshRNA
DOCA-HS vs.

Yes

45.23

HS
Control vs.

-36.22 to

26.10

DOCA+OX1RshRNA

T3

ns

-0.07364

DOCA+OX1RshRNA
DOCA-HS vs.

No

34.80

HS
Control vs.

-3.297 to

-46.77 to
-10.63

-7.18

DOCA+OX1RshRNA

-25.25 to
10.89

109

DOCA-HS vs.

21.52

2.469 to

DOCA+OX1RshRNA

T5

Control vs. DOCA-

Yes

*

Yes

****

No

ns

Yes

**

40.57

-34.52

-52.59 to

HS

-16.45

Control vs.

-7.788

-25.86 to

DOCA+OX1RshRNA
DOCA-HS vs.

10.28
26.73

7.681 to

DOCA+OX1RshRNA

45.78

Table B.38: Two-way ANOVA analysis of 3-week HR between groups.
Heart Rate
ANOVA

%Total

P Value

P Value

Significant?

Summary

Variation

Interaction

7.599

0.8304

ns

No

Row Factor

4.839

0.605

ns

No

Column Factor

7.824

0.0603

ns

No

ANOVA Table

SS

DF

MS

P value

Summary

110

Interaction

34118

10

3412

P = 0.8304

Row Factor

21726

5

4345

P = 0.6050

Column Factor

35129

2

17565

P = 0.0603

Residual

358005

60

5967

Total

448978

77
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